WO2006127355A2 - Oral drug compliance monitoring using radio frequency identification tags - Google Patents

Oral drug compliance monitoring using radio frequency identification tags Download PDF

Info

Publication number
WO2006127355A2
WO2006127355A2 PCT/US2006/019079 US2006019079W WO2006127355A2 WO 2006127355 A2 WO2006127355 A2 WO 2006127355A2 US 2006019079 W US2006019079 W US 2006019079W WO 2006127355 A2 WO2006127355 A2 WO 2006127355A2
Authority
WO
WIPO (PCT)
Prior art keywords
rfid tag
capsule
tablet
pill
gastrointestinal system
Prior art date
Application number
PCT/US2006/019079
Other languages
French (fr)
Other versions
WO2006127355A3 (en
Inventor
Peter Kip Mercure
Christopher M. Jones
Malcolm W. Warren
Susan J. Babinec
Mark T. Bernius
Flor A. Castillo
Paul E. Cranley
Kristine L. Danowski
Mark Sb Felix
Robert B. Fletcher
Robert Paul Haley
Thomas H. Kalantar
Chris W. Mcdougall
Michelle A. Pressler
Bettina M. Rosner
Jaime Simon
Deidre A. Strand
Larry Sun
Douglas P. White
Original Assignee
Dow Global Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc. filed Critical Dow Global Technologies Inc.
Priority to CA002609007A priority Critical patent/CA2609007A1/en
Priority to JP2008512470A priority patent/JP4933538B2/en
Priority to EP06770493A priority patent/EP1885343B1/en
Priority to CN2006800251198A priority patent/CN101217945B/en
Priority to DK06770493.2T priority patent/DK1885343T3/en
Priority to AT06770493T priority patent/ATE526952T1/en
Publication of WO2006127355A2 publication Critical patent/WO2006127355A2/en
Publication of WO2006127355A3 publication Critical patent/WO2006127355A3/en

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/04—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the shape
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K11/00—Marking of animals
    • A01K11/006—Automatic identification systems for animals, e.g. electronic devices, transponders for animals
    • A01K11/007—Boluses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/007—Marking tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/073—Special arrangements for circuits, e.g. for protecting identification code in memory
    • G06K19/07309—Means for preventing undesired reading or writing from or onto record carriers
    • G06K19/07318—Means for preventing undesired reading or writing from or onto record carriers by hindering electromagnetic reading or writing
    • G06K19/07327—Passive means, e.g. Faraday cages
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/073—Special arrangements for circuits, e.g. for protecting identification code in memory
    • G06K19/07309—Means for preventing undesired reading or writing from or onto record carriers
    • G06K19/07318—Means for preventing undesired reading or writing from or onto record carriers by hindering electromagnetic reading or writing
    • G06K19/07336—Active means, e.g. jamming or scrambling of the electromagnetic field
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/073—Special arrangements for circuits, e.g. for protecting identification code in memory
    • G06K19/07309—Means for preventing undesired reading or writing from or onto record carriers
    • G06K19/07345—Means for preventing undesired reading or writing from or onto record carriers by activating or deactivating at least a part of the circuit on the record carrier, e.g. ON/OFF switches
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
    • G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
    • G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
    • G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
    • G06K19/077—Constructional details, e.g. mounting of circuits in the carrier
    • G06K19/07749—Constructional details, e.g. mounting of circuits in the carrier the record carrier being capable of non-contact communication, e.g. constructional details of the antenna of a non-contact smart card
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K7/00—Methods or arrangements for sensing record carriers, e.g. for reading patterns
    • G06K7/0008—General problems related to the reading of electronic memory record carriers, independent of its reading method, e.g. power transfer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K7/00—Methods or arrangements for sensing record carriers, e.g. for reading patterns
    • G06K7/10—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation
    • G06K7/10009—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation sensing by radiation using wavelengths larger than 0.1 mm, e.g. radio-waves or microwaves
    • G06K7/10019—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation sensing by radiation using wavelengths larger than 0.1 mm, e.g. radio-waves or microwaves resolving collision on the communication channels between simultaneously or concurrently interrogated record carriers.
    • G06K7/10079—Methods or arrangements for sensing record carriers, e.g. for reading patterns by electromagnetic radiation, e.g. optical sensing; by corpuscular radiation sensing by radiation using wavelengths larger than 0.1 mm, e.g. radio-waves or microwaves resolving collision on the communication channels between simultaneously or concurrently interrogated record carriers. the collision being resolved in the spatial domain, e.g. temporary shields for blindfolding the interrogator in specific directions
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/12—Supports; Mounting means
    • H01Q1/22—Supports; Mounting means by structural association with other equipment or articles
    • H01Q1/2208—Supports; Mounting means by structural association with other equipment or articles associated with components used in interrogation type services, i.e. in systems for information exchange between an interrogator/reader and a tag/transponder, e.g. in Radio Frequency Identification [RFID] systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/27—Adaptation for use in or on movable bodies
    • H01Q1/273—Adaptation for carrying or wearing by persons or animals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q1/00—Details of, or arrangements associated with, antennas
    • H01Q1/36—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith
    • H01Q1/362—Structural form of radiating elements, e.g. cone, spiral, umbrella; Particular materials used therewith for broadside radiating helical antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q11/00—Electrically-long antennas having dimensions more than twice the shortest operating wavelength and consisting of conductive active radiating elements
    • H01Q11/02—Non-resonant antennas, e.g. travelling-wave antenna
    • H01Q11/08—Helical antennas
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01Q—ANTENNAS, i.e. RADIO AERIALS
    • H01Q7/00—Loop antennas with a substantially uniform current distribution around the loop and having a directional radiation pattern in a plane perpendicular to the plane of the loop
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/30—Compliance analysis for taking medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules

Definitions

  • the instant invention relates to oral drug compliance monitoring, and, more particularly, to the use of radio frequency identification tags ingested by the patient with a drug formulation.
  • Non-compliance of patients to drug regimens prescribed by their physicians results in increased cost of medical care, higher complication rates, as well as drug wastage.
  • Non-compliance refers to the failure to take the prescribed dosage at the prescribed time which results in undermedication or overmedication. In a survey of 57 non-compliance studies, non-compliance ranged from 15% to as high as 95% in all study populations, regardless of medications, patient population characteristics, drug being delivered or study methodology (Greenberg, Clinical Therapeutics, 6(5):592-599, 1984).
  • accurately measuring compliance can lead to benefits such as: improved statistical reliability of a clinical study; clinical studies being completed sooner; and a determination of the effect of non-compliance as a function of the degree of non-compliance.
  • accurately measuring compliance has a number of important benefits such as: warning a patient about the potential for developing a drug resistant infection related to poor compliance; and identifying a side effect of a drug related to overdosing.
  • Compliance to the instructions given to patients during any clinical trial is usually less than 50% in relatively short-term and less than 40% in longer-term trials using traditional methods (e.g., paper diaries) for making entries to show compliance (Vrijens and Goetghebeur, Statist. Med. 23, 531-544, 2004).
  • a clinical trial on chronic pain patients reported only an 11% compliance with as high as 80% fake entries when paper diaries secretly instrumented to tract diary usage were given to patients (Stone et al., Control Clin. Trials. 24, 182-199, 2003) wherein on 32% of study days the paper diary was not opened, yet the compliance entries for those days exceeded 90%.
  • blood levels of a drug can be corrected for the time of actual drug intake for better pharmacokinetic/ pharmacodynamic interpretations than relying on the time when patient(s) was instructed to take the medication.
  • most of the present tracking devices that are utilized in clinical trials only track the initiation of the process of drug intake, i.e., by tracking the time the drug containers are opened or activated. In order to more accurately monitor the compliance of a clinical trial, a more sophisticated method of monitoring the drug intake is needed.
  • Transdermal detection devices attached to the skin of a patient have been developed which detect ingested drug components through the skin and such devices can transmit a signal to a remote receiver at an external site such as a healthcare facility, see USP 6,663,846 and USPAP 2005/0031536.
  • Electronic sensor systems have been developed which detect ingested drug components in the breath of a patient, see USPAP 2004/0081587.
  • Radio frequency identification (RFID) tags have been incorporated into drug pills, each tag capable of identifying the type of medication, its dosage, and its lot number by way of a unique code emitted by the tag when interrogated by a corresponding radio frequency "reader", see USP 6,366,206.
  • the RFID of the '206 patent can incorporate a biosensor that detects, for example, a change in pH to determine whether the pill has dissolved and exposed the RFID tag to the environment of the gastrointestinal system.
  • the technology of the '206 patent requires a highly specialized spherical RFID semiconductor and biosensor. It would be an advance in the art if RFID technology could be used in a less complex manner.
  • the instant invention is a solution, at least in part, to the above stated problems.
  • the instant invention provides a number of new and improved alternatives for determining drug compliance using RFID tags.
  • the instant invention is a device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that the capsule, tablet or pill has dispersed in the gastrointestinal system.
  • the instant invention is a device useful for oral drug delivery, comprising: (a) a tablet, pill or capsule designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the tablet, pill or capsule, the RFID tag comprising a switch, the switch turning on or off in response to conditions in the gastrointestinal system so that if the RFID tag is interrogated before the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the capsule has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the tablet, pill or capsule has dispersed in the gastrointestinal system.
  • the instant invention is a device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non- anti-collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti- collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.
  • Fig. 1 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a gelatin capsule containing a pair of ferrite rings over an RFID tag;
  • Fig. 2 is an enlarged view of the oral drug delivery system of Fig. 1 after the capsule has dispersed in the gastrointestinal system;
  • Fig. 3 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a tablet or pill containing a cylindrical magnet over an RFID tag;
  • Fig. 4 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a drug tablet containing pair of ferrite disks positioned at either end of an RFID tag;
  • Fig. 5 is an enlarged view part in cross-section, part broken away and part in full, of an oral drug delivery system comprising a capsule containing a magnet positioned in a cavity of an RFID tag adjacent the antenna coil of the RFID tag;
  • Fig. 6 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a drug tablet containing an iron rod positioned adjacent an RFID tag;
  • Fig. 7 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RFID tag having an antenna shielded by a cup of gold foil
  • Fig. 8 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RPID tag having an antenna shielded by particles of gold embedded in the gelatin capsule;
  • Fig. 9 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RFID tag having an antenna shielded by particles of gold embedded in a gum arabic coating on the RFID tag;
  • Fig. 10 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an RFID tag having an antenna shielded by particles of gold embedded in a gum arabic coating on the RFID tag;
  • Fig. 11 is an enlarged view of an RFID tag having an external fine iron wire shorting the antenna of the RFID tag;
  • Fig. 12 is an enlarged view of the RFID tag of Fig. 11 after the RFID tag has been exposed to gastric juices for ten minutes to corrode and sever the fine iron wire;
  • Fig. 13 is an enlarged side view, part in cross-section and part in full, of a switch which turns on if exposed to gastric juices;
  • Fig. 14 is an enlarged side view, part in cross-section and part in full, of the switch of Fig. 13 after exposure to gastric juices;
  • Fig. 15 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an active RFID tag powered by a kinetic generator and incorporating a conductivity switch;
  • Fig. 16 is a schematic drawing showing the conductivity switch of Fig. 15 in greater detail
  • Fig. 17 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag powered by a battery activated by the action of the electrolyte of the gastrointestinal system in contact with the anode and cathode of the battery;
  • Fig. 18 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag and a dissolving link switch;
  • Fig. 19 is an enlarged view, part in cross-section and part in full, of a drug capsule containing an active RFID tag and a switch based sensor
  • Fig. 20 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag and a capacitor based switch
  • Fig. 21 is an enlarged view, part in cross-section and part in full, of a drug capsule containing an active RFID tag and a temperature based switch
  • Fig. 22 is a schematic view of a typical prior art RFID system including a passive RFID tag and an RFID reader or interrogator;
  • Fig. 23 shows a cross-sectional view of a gelatin capsule containing a pair of passive non-anti-collision RFID tags being interrogated by an RFID reader;
  • Fig. 24 shows a cross-sectional view of a tablet containing a pair of passive non-anti- collision RFID tags being interrogated by an RFID reader;
  • Fig. 25 shows a spaced apart pair of passive non-anti-collision RFID tags being interrogated by an RFID reader.
  • an oral drug delivery system 10 of the instant invention comprising an upper gelatin capsule portion 11 and a lower gelatin capsule portion 12.
  • a Texas Instruments low frequency RFID tag 14 is positioned within the capsule of the system 10.
  • the tag 14 is encapsulated in glass and includes an RFID chip encoded to identify a drug type, dose, lot number etc.
  • the tag 14 includes an antenna.
  • the remaining volume within the capsule of the system 10 is, of course, available to contain a drug formulation 13.
  • a pair of ferrite rings 15 and 16 are positioned around the RFID tag 14 to alter the antenna characteristics of the RFID tag so that if the RFID tag 14 is interrogated before the capsule 11/12 disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated by the ferrite rings 15/16 to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system.
  • alter the antenna characteristics of the RFID tag means to change the resonate frequency of the antenna and/or to reduce the effective signal strength from the antenna.
  • the specific RFID tag used in the instant invention is not critical. For example, the RFID tag does not have to be a low frequency RFID tag.
  • the RFID tag should be sufficiently encapsulated or otherwise protected so that it works long enough in the environment of the gastrointestinal system to fulfill its purpose.
  • the RFID tag can be preprogrammed or programmable as is well understood in the art. Any type of RFID tag can be used in the instant invention.
  • the RFID tag is preferably a passive RFID tag powered by the a signal from the RFID reader.
  • an active RFID tag powered, for example, by a battery associated with the RFID tag
  • Fig. 2 when the oral drug delivery system of Fig.
  • capsules useful in the instant invention can be made of materials other than gelatin, such as hydroxypropylmethylcellulose.
  • the capsule of the instant invention can also be made of a material, such as poly (N,N-9- diethylaminoethyl methacrylate), which disperses in an acid environment but not in water.
  • the RFID reader system is battery powered and contained in a pouch worn around the waist by a belt.
  • the RFID reader can be programmed to sense and record the type of drug(s) and times of administration thereof for later downloading or preferably for wireless downloading to, for example, healthcare professionals who could even send a reminder signal to the system to remind the patient of his/her noncompliance.
  • an RFID reader system can be incorporated into a watch-like appliance worn on the wrist.
  • an RFID reader system could be clipped to a belt not unlike a cell phone clipped to a belt.
  • an oral drug delivery system 20 comprising a tablet or pill 21 containing a cylindrical magnet 22 over an RFID tag 23.
  • the magnet 22 alters the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the tablet or pill 21 disperses in the gastrointestinal system, the response of the RFID tag 23 is sufficiently altered or attenuated to determine that the tablet or pill 21 has not dispersed in the gastrointestinal system and so that if the RFID tag 23 is interrogated after the tablet or pill 21 has dispersed in the gastrointestinal system, the cylindrical magnet 22 separates from the RFID tag 23 so that the response of the RFID tag 23 is sufficiently detectable to determine that the tablet or pill 21 has dispersed in the gastrointestinal system.
  • FIG. 4 therein is shown is an enlarged view, part in cross- section and part in full, of an oral drug delivery system 30 comprising a drug tablet 31 containing a pair of ferrite disks 32/33 positioned at either end of an RFID tag 34.
  • the ferrite disks 32/33 alter the antenna characteristics of the RFID tag 34 so that if the RFID tag 34 is interrogated before the tablet 31 disperses in the gastrointestinal system, the response of the RFID tag 34 is sufficiently altered or attenuated to determine that the tablet 31 has not dispersed in the gastrointestinal system and so that if the RFID tag 34 is interrogated after the tablet 31 has dispersed in the gastrointestinal system, the ferrite disks 32/33 separate from the RFID tag 34 so that the response of the RFID tag 34 is sufficiently detectable to determine that the tablet 31 has dispersed in the gastrointestinal system.
  • FIG. 5 therein is shown an enlarged view part in cross- section, part broken away and part in full, of an oral drug delivery system 40 comprising a capsule 41/42 containing a magnet 43 positioned in a cavity of an RFID tag 44 adjacent the antenna coil 45 of the RFID tag 44.
  • the magnet 43 alters the antenna characteristics of the RFID tag 44 so that if the RFID tag 44 is interrogated before the system 40 disperses in the gastrointestinal system, the response of the RFID tag 44 is sufficiently altered or attenuated to determine that the system 40 has not dispersed in the gastrointestinal system and so that if the RFID tag 44 is interrogated after the system 40 has dispersed in the gastrointestinal system, the magnet 43 separates from the RFID tag 44 so that the response of the RFID tag 44 is sufficiently detectable to determine that the system 40 has dispersed in the gastrointestinal system.
  • the cavity of the RFID tag can, for example and without limitation thereto, be filled with a dispersible ferrite composition that will disperse in the gastrointestinal system when the system 40 is ingested.
  • an oral drug delivery system 50 comprising a drug tablet 51 containing an iron rod 52 positioned adjacent an RFID tag 53.
  • the iron rod 52 alters the antenna characteristics of the RFID tag 53 so that if the RFID tag 53 is interrogated before the system 50 disperses in the gastrointestinal system, the response of the RFID tag 53 is sufficiently altered or attenuated to determine that the system 50 has not dispersed in the gastrointestinal system and so that if the RFID tag 53 is interrogated after the system 50 has dispersed in the gastrointestinal system, the iron rod 52 separates from the RFID tag 53 so that the response of the RFID tag 53 is sufficiently detectable to determine that the system 50 has dispersed in the gastrointestinal system.
  • an oral drug delivery system 10a of the instant invention comprising an upper gelatin capsule portion 11a and a lower gelatin capsule portion 13 a.
  • a Texas Instruments low frequency RFID tag 14a is positioned within the capsule of the system 10a.
  • the tag 14a is encapsulated in glass 15a and includes an RFID chip 16a encoded to identify a drug type, dose, lot number etc.
  • the tag 14a includes a copper coil antenna 18a having a ferrite core 19a in communication with the chip 16a and a capacitor 17a.
  • the remaining volume 20a within the capsule of the system 10a is, of course, available to contain a drug formulation.
  • the RFID tag can be pre-programmed or programmable as is well understood in the art.
  • the copper coil antenna 18a and ferrite core 19a are a preferred antenna system for the RFID tag 14a of the instant invention because this antenna system is compact even though the wavelength of operation is relatively long.
  • a conventional dipole antenna of the same size as the copper coil antenna 18a requires a relatively short wavelength of operation which can complicate or even frustrate electromagnetic wave communication through human tissue since such short wavelength radiation is easily absorbed or attenuated by water.
  • a cup of gold foil 12a is positioned inside the upper gelatin capsule portion 11a.
  • an RFID reader such as the RFID reader available from, for example, Texas Instruments or from the Stoelting Company (Wood Dale, IL) it fails to respond because the gold foil 12a shields the antenna 18a.
  • the capsule portions 11a and 13a disperse in the stomach or intestinal tract thereby freeing the RFID tag 14a from the shielding effect of the gold foil cup 12a so that the RFID tag 14a will now respond to an RFID reader.
  • the upper gelatin capsule portion 1 Ia is dispersible in the stomach or intestinal tract. However, it is not critical in the embodiment shown in Fig. 7 that the upper capsule portion is so dispersible since the RFID tag will separate from the gold foil 12a as long as the lower capsule portion 13a disperses in the stomach or intestinal tract. Although it is preferable to place the gold foil 12a inside the upper capsule portion 1 Ia as shown in Fig. 1, the gold foil 12a can be placed on the outside of the upper capsule portion 11a. Although gold is the preferred material to shield the antenna 18a of the RFID tag 14a, any metal or other material can be used that is effective to shield the electromagnetic waves and which is approved for ingestion (e.g., iron and nickel are listed by the FDA as Generally Recognized As Safe for ingestion).
  • capsules useful in the instant invention can be made of materials other than gelatin, such as hydroxypropylmethylcellulose.
  • the capsule of the instant invention can also be made of a material, such as a polymer comprising N,N-9- diethylaminoethyl methacrylate, which disperses in an acid environment but not in water.
  • materials such as polymers comprising N,N-9-diethylaminoethyl methacrylate, hydroxypropylmethylcellulose or gelatin can be used instead of gum arabic as a coating material to contain the electromagnetic shielding material.
  • FIG. 8 therein is shown another oral drug delivery system 21a of the instant invention, comprising an upper gelatin capsule portion 23 a and a lower gelatin capsule portion 22a.
  • a Texas Instruments low frequency RFID tag 25 a is positioned within the capsule of the system 21a.
  • the tag 25a is encapsulated in glass 26a and includes an RFID chip 27a encoded to identify a drug type, dose, lot number etc.
  • the tag 25a includes a copper coil antenna 29a having a ferrite core 30a in communication with the chip 27a and a capacitor 28a.
  • the remaining volume 3 Ia within the capsule of the system 21a is, of course, available to contain a drug formulation.
  • the upper capsule 23 a comprises particles of gold 24a.
  • the system 21 a When the system 21 a is interrogated with an RFID reader it fails to respond because the gold particles 24a shield the antenna 29a. However, when the system 21a is swallowed the capsule portions 23 a and 22a disperse in the stomach or intestinal tract thereby freeing the RFID tag 25a from the shielding effect of the gold particles 24a so that the RFID tag 25a will now respond to an RFID reader.
  • the lower gelatin capsule portion 22a is dispersible in the stomach or intestinal tract. However, it is not critical in the embodiment shown in Fig. 8 that the lower capsule portion is so dispersible since the RFID tag will separate from the lower capsule portion 22a as long as the upper capsule portion 23 a disperses in the stomach or intestinal tract.
  • FIG. 9 therein is shown another oral drug delivery system 32a of the instant invention, comprising an upper gelatin capsule portion 34a and a lower gelatin capsule portion 33a.
  • a Texas Instruments low frequency RFID tag 35a is positioned within the capsule of the system 32a.
  • the tag 35a is encapsulated in glass 36a and includes an RFID chip 37a encoded to identify a drug type, dose, lot number etc.
  • the tag 35a includes a copper coil antenna 39a having a ferrite core 40a in communication with the chip 37a and a capacitor 38a.
  • the remaining volume 43a within the capsule of the system 32a is, of course, available to contain a drug formulation.
  • the upper end of the RFID tag 35a is coated with a layer of gum arabic 41a containing particles of gold 42a.
  • FIG. 10 therein is shown another oral drug delivery system 44a of the instant invention, comprising a tablet or pill 45a containing a drug formulation.
  • a Texas Instruments low frequency RFID tag 46a is positioned within the tablet or pill 45a.
  • the tag 46a is encapsulated in glass 47a and includes an RFID chip 48a encoded to identify a drug type, dose, lot number etc.
  • the tag 46a includes a copper coil antenna 50a having a ferrite core 5 Ia in communication with the chip 48a and a capacitor 49a.
  • the RFID tag 46a is coated with a layer of gum arabic 52a containing particles of gold 53a. When the system 44a is interrogated with an RFID reader it fails to respond because the gold particles 53 a shield the antenna 50a.
  • the tablet or pill 45a as well as the gum arabic 52a disperses in the stomach or intestinal tract thereby freeing the RFID tag 46a from the shielding effect of the gold particles 53a so that the RFID tag 46a will now respond to an RFID reader.
  • the layer of gum arabic 52a containing the gold particles 53a can also positioned on the surface of the tablet or pill 45a.
  • the instant invention is an oral drug delivery device, comprising: (a) a drug tablet, pill or capsule designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the tablet, pill or capsule, the RFID tag comprising a switch, the switch turning on or off in response to conditions in the gastrointestinal system so that if the RFID tag is interrogated before the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the capsule has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RPBD tag signifies that the tablet, pill or capsule has dispersed in the gastrointestinal system.
  • the switch preferably turns on the RFID tag after the tablet, pill or capsule has dispersed in the gastrointestinal system (and thus the term "interrogate" throughout the instant invention includes reading the signal from such an active RFID tag).
  • the switch can be used to change a logic function of the RFID tag.
  • an RFID tag 54a having a thin iron wire 55a projecting therefrom.
  • the iron wire 55a serves as a "switch" for the RFID tag, turning the RFID tag off or preferably on when the iron wire 55a is severed.
  • the iron wire 55a can be positioned to short the antenna of the RFID tag 54a so that when the iron wire 55a is severed, the RFID tag 54a will respond to an RFID reader.
  • Fig. 12 therein is shown the RFID tag 54a of Fig. 11 after the RFID tag 54a has been exposed to the acidic conditions of the stomach.
  • the thin iron wire 55a has been severed by corrosion.
  • the RFID tag 11 can thus be placed in a drug capsule or processed in a drug tablet or pill so that when the capsule, tablet or pill is ingested, the RFID tag will then respond to an RFID reader.
  • other materials can be used in place of the iron wire 55a such as an electrically conductive material that disperses upon exposure in the gastrointestinal system such as a layer of a polymer comprising N,N-9- diethylaminoethyl methacrylate containing a relatively high concentration of gold particles printed on the capsule or tablet so that before its dispersion in the gastrointestinal system, the layer is electrically conductive.
  • a switch system for an RFID tag (not shown) for turning the RFID tag on when the contacts of the switch are closed.
  • the switch system of Fig. 13 includes a small case 56a having a water permeable disk 57a and a water swellable gel 62a.
  • An upper contact 59a is connected to a first electrical lead 58a extending from the case 56a.
  • a lower contact 60a is connected to a second electrical lead 61a extending from the bottom of the case 56a.
  • Fig. 15 therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 10b of the instant invention including an upper gelatin capsule portion l ib and a lower gelatin capsule portion 12b.
  • the gelatin capsule 1 lb/12b contains a drug formulation 13b and an active encapsulated RFID tag 14b powered by a kinetic generator and incorporating a conductivity detector.
  • the kinetic generator is comprised of a magnet 18b suspended in a coil 17b.
  • the capacitor 19b provides power to RFID circuitry 16b.
  • Electrodes 20ab and 20bc of a conductivity detector system activate the RFID circuitry 16b when the conductivity detector system senses the conductivity of the electrolyte solution of the gastrointestinal system.
  • RFID circuitry 16b is connected to antenna 15b (shown as a copper coil would on a ferrite core) which transmits a signal preferably coded to identify the drug formulation, dose and lot number.
  • antenna 15b shown as a copper coil would on a ferrite core
  • the kinetic generator system is replaced by a battery.
  • FIG. 16 therein is shown a schematic drawing of the conductivity detector of Fig. 15 in greater detail.
  • a p-FET transistor 22b and bias resistor 21b are incorporated to activate the RFID circuitry 16b from capacitor 19b when the conductivity of the electrolyte solution of the gastrointestinal system is detected by way of the electrodes 20ab and 20bg.
  • the p-FET circuit could be replaced by an n- FET 5 CMOS gate, or other electronic circuits using electronic design methods well known in the art.
  • a drug tablet 30b containing a drug formulation 31b and an active RFID tag 32b powered by a battery activated by the action of the electrolyte solution of the gastrointestinal system in contact with the copper anode 33b and zinc cathode 34b of the battery.
  • the switch and the RFID power source are unified, i.e., when the RFID tag of tablet 30b is dispersed in the gastrointestinal system, the electrolyte solution thereof generates the electrical power for the RFID tag 32b by way of the copper anode 33b and zinc cathode 34b.
  • the use of copper in the anode and zinc in the cathode of this embodiment are not critical in the instant invention, i.e., any suitable pair of materials can be used such as carbon and zinc or silver and zinc.
  • Fig. 18 therein is shown an enlarged view, part in cross- section and part in full, of a drug tablet 40b containing drug formulation 41b and an active RFID tag 42b containing RFID circuitry 43b connected to antenna system 45b.
  • the RFID circuitry 43b is powered by battery 44b.
  • An electrically conducting layer of powdered silver, carbon, or other conductive material in gelatin 48b provides electrical conduction between electrodes 46b and 47b such that when the tablet 40b disperses in the gastrointestinal tract, the electrolyte solution thereof dissolves the gelatin 48b and alters the electrical conductivity between electrodes 46b and 47b thereby activating RFID circuitry 43b.
  • Fig. 19 therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 50b of the instant invention including an upper gelatin capsule portion 51b and a lower gelatin capsule portion 52b.
  • the gelatin capsule 51b/52b contains a drug formulation 53b and an active encapsulated RFID tag 54b containing RFID circuitry 55b connected to antenna system 57b.
  • the RFID circuitry 55b is powered by battery 56b.
  • a pad of water swellable polymer 60b is positioned so that when the oral drug delivery system 50b is dispersed in the gastrointestinal system, the electrolyte solution thereof swells the water swellable polymer 60b causing electrical conductor 58b to contact electrical conductor 59b altering the electrical conductivity between the conductors 58b and 59b thereby activating RFID circuitry 55b.
  • the swelling of the water swellable polymer 60b could easily be arranged to open a switch rather than closing a switch.
  • the swelling of a water swellable polymer could easily be arranged to open a switch of the type shown in Fig. 19 or to break a thin wire.
  • the space between conductors 58b and 59b could be filled with a soluble material that would dissolve in the gastrointestinal system allowing the conductors to touch and close the switch.
  • a pressure switch could be used to sense the increased pressure when the active RFID tag of the instant invention was dispersed in the gastrointestinal tract.
  • Fig. 20 therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery tablet 61b of the instant invention.
  • the tablet 61b contains a drug formulation 62b and an active encapsulated RFID tag 63b containing RFID circuitry 64b connected to antenna system 66b.
  • the RFID circuitry 64b is powered by battery 65b.
  • a film of water swellable polymer 68b is positioned between first capacitor plate 69b and second capacitor plate 70b so that when the oral drug delivery system 61b is dispersed in the gastrointestinal tract, the electrolyte solution thereof swells the water swellable polymer 70b altering the capacitance between plates 69b and 70b thereby activating RFID circuitry 55b via electrical conductors 67b and 68b.
  • the capacitor plates 69b and 70b could comprise conductive wires or pads placed near the surface of 63 b such that the dielectric constant of the surroundings would change with ingestion (from air to gastrointestinal electrolyte) altering the capacitance thereby activating the RFID circuitry.
  • Fig. 21 therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 70b of the instant invention including an upper gelatin capsule portion 71b and a lower gelatin capsule portion 72b.
  • the gelatin capsule 71b/72b contains a drug formulation 73b and an active encapsulated RFID tag 74b containing RFID circuitry 75b connected to antenna system 77b.
  • the RFID circuitry 75b is powered by battery 76b.
  • a thermistor 78b is in electrical communication with RFID circuitry 75b so that when the oral drug delivery system 70b is dispersed in the gastrointestinal tract the RFID circuitry 75b can sense the change in temperature thereby and begin sending (or altering) its signal via the antenna system 77b.
  • the RFID circuitry 75b is preferably programmed to differentiate between the temperature profile with time that occurs when a patient swallows the oral drug delivery system 70b versus placing the oral drug delivery system 70b in, for example, a glass of hot water.
  • a temperature sensitive switch can be used instead of the thermistor 78b.
  • the instant invention is an oral drug delivery device, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non-anti- collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti- collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.
  • a schematic view of a typical RFID system 10c including a passive RFID tag 1 Ic and an RFID reader or interrogator 12c which is usually associated with a host computer or microprocessor system 13c for data storage and manipulation.
  • the RFID reader or interrogator 12c transmits a radio frequency energizing/command signal 14c which is received by the RFID tag 1 Ic to produce a return data signal 15c to be received by the reader 12c.
  • Fig. 23 shows a cross-sectional view of a gelatin capsule 21 c/22c containing a drug formulation 25c, a first non-anti-collision passive RFID tag 23c, a second non-anti-collision passive RFID tag 24c, so that if the RFID tags 23c and 24c are interrogated by energizing/command signal 28c from an RFID reader 26c before the capsule 21c/22c disperses in the gastrointestinal system, the response data signals 29c of the RFID tags 23c/24c "collide".
  • An active RFID tag is an RFID tag having its own power source, usually a battery.
  • a passive RFID tag is an RFID tag powered by an incoming radio frequency signal.
  • non-anti- collision RFID tag means an RFID tag whose data signal will collide with and interfere with the data signal from another non-anti-collision RFID tag at the RFID reader. Since the RFID tags 23c and 24c are non-anti-collision tags and since the RFID tags 23c and 24c are together in the capsule system 21c/22c, the data signals 29c from the RFID tags 23c and 24c collide at the reader 26c.
  • a computer or microprocessor system 27c is provided for data storage and manipulation.
  • Fig. 24 therein is shown shows a cross-sectional view of a tablet 30c containing a drug formulation 31c, a first non-anti-collision active RFID tag 32c, a second non-anti-collision active RFID tag 33c, so that if the RFID tags 32c and 33c are interrogated by RFID reader 34c before the tablet 30c disperses in the gastrointestinal system, the data signal 37c of the RFID tags 32c/33c "collide" at the reader 34c.
  • a computer or microprocessor system 35c is provided for data storage and manipulation.
  • a spaced apart pair of passive non- anti-collision RFID tags 41c and 42c (for example if they are separated in the gastrointestinal system) being interrogated by energizing/command signal 45c/47c from an RFID reader 43c.
  • the RFID tags 41c and 42c produce data signals 46c and 48c to be received by the reader 43 c.
  • the RFID tag 41c is sufficiently closer to the reader 43 c than the RFID tag 42c, such that the data signals 46c and 48c can be differentiated by the reader 43 c.
  • a computer or microprocessor system 44c is provided for data storage and manipulation.
  • a pair of active or passive non-anti-collision RFID tags are used in the instant invention.
  • Each non-anti-collision RFID tag is preferably encoded to identify (via its data signal) the drug type, dose and lot number.
  • the specific non-anti-collision RFID tags used in the instant invention are not critical. However, it is preferred that the RFID tag be encapsulated with an inert material such as glass.
  • a series of six uniquely coded glass encapsulated animal permanent identification RFID tags (Stoelting Company, Wooddale IL) are covered with ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1).
  • the capsules are each interrogated with a portable RFID reader (Allflex ISO Compatible RF/ID Portable Reader Model No. 930002-001) but the reader indicates "No Tag Found".
  • the capsules are placed in a series of one liter beakers containing 900 mL of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation. The capsules disperse and the reader held at a distance of about 10 centimeters from each RFID tag responds "Tag Found" at the following times: 1.50, 1.80, 1.85, 1.87, 1.88 and 1.95 minutes.
  • EXAMPLE 2 A series of six uniquely coded glass encapsulated animal permanent identification
  • RFID tags (Stoelting Company, Wooddale IL) are covered with ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1 except that three ferrite rings are used).
  • the capsules are each interrogated with a portable RFID reader (Allflex ISO Compatible RF/ID Portable Reader Model No. 930002-001) but the reader indicates "No Tag Found".
  • the capsules are placed in a series of one liter beakers containing 900 niL of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation. The capsules disperse and the reader held at a distance of about 10 centimeters from each RFID tag responds "Tag Found" at the following times: 1.58, 2.22, 2.33, 3.25, 3.50 and 7.92 minutes.
  • a series of uniquely coded glass encapsulated animal permanent identification RFID tags (Stoelting Company, Wooddale IL) are covered with a pair of ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1).
  • Four healthy adult beagle dogs are dosed orally with a single capsule containing the RFID tags and ferrite rings.
  • the receiver (Stoelting Company, Wooddale IL) is held manually within ⁇ 2 cm from the skin of the dog's abdominal region.
  • the time for the first reading of the RFID tag after dissolution of the capsule and release of ferrite sleeves is determined at 1 -minute intervals until the first reading is successfully achieved. Subsequent signals are read over time (1,2,4, 8 and 24 hours) thereafter until the RFID tags and ferrite rings passed through the gastrointestinal (GI) tract to be recovered from the collected feces. The time for the RFID tags and ferrite rings to pass through the GI tract and its appearance in the feces is also monitored at each collection interval (e.g., 0-24 and 24-48 hours).
  • the dogs in an initial experiment have free access to feed, both prior to and after dosing.
  • the dogs in a subsequent experiment fasted overnight (-16 hours) then had free access to feed 4 hours after dosing.
  • radio signals are read within 10.3 ⁇ 5.1 minutes after dosing with individual variation of 4 to 16 minutes. Overnight fasting prior to dosing reduces the time to the first signal detection to 6 ⁇ 1 minutes after dosing with a lower individual variation between 5 and 7 minutes.
  • the radio signals emitted by the RFID tag are easily read by the RFID reader at subsequent time points (1,2,4,8 and 24 hours after dosing) indicating location of the device within different regions of the GI tract. All of the devices are recovered from the feces within 24-30 hours from non-fasted and between 24-48 hours from the fasted dogs. Readability of the radio signals emitted from the RFID tags is within 2-3 cm from the animal body with the exception of one tag whose signals are strong enough to be read from 10-12 cm away from the body.
  • a 433 MHz passive RFID tag is positioned in a gold foil modified gelatin capsule containing a drug formulation substantially as shown in Fig. 7.
  • the capsule is interrogated with a portable RFID reader (Intermec IP3 Intellitag Portabe Reader) but the reader indicates "No Tag Found”.
  • the capsule is placed in 900 mL of USP Simulated Gastric Fluid in a one liter beaker at 37 degrees Celsius with agitation. The capsule disperses after about two minutes and the reader held at a distance of about 10 centimeters from the one liter beaker responds "Tag Found".
  • a 433 MHz active RFID tag having a conductivity switch is positioned in a large gelatin capsule containing a drug formulation substantially as shown in Fig. 15 (except the RFID tag is battery powered and the antenna is spiral wound in a dielectric).
  • the capsule is placed in a plastic wire screen basket placed in the center of a 50 liter polyethylene tank containing 40 liters of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation.
  • a receiving dipole antenna is positioned at the bottom of the tank. Another receiving dipole antenna is positioned outside the tank.
  • the gelatine capsule disperses in the simulated gastric fluid and the conductivity switch turns on the RFID tag which then transmits its 433 MHz signal.
  • the signal strength received by the antenna in the tank is about 5 nanowatt.
  • the signal strength received by the antenna outside the tank held against the tank is about 0.1 nanowatt.
  • the signal strength received by the antenna outside the tank held 70 centimeters away from the tank is about 0.01 nanowatt.
  • An arm held between the tank and the antenna slightly (2-3 dB) reduces the signal strength received by the antenna.
  • the minimum detectable signal strength received by the antenna outside the tank held even further from the tank is estimated to be about 0.0001 nanowatt.
  • the signal strength received by the antenna outside the tank is only slightly dependent (a variation of about 1-5 dB) on the position of the antenna of the RFID tag.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Theoretical Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Electromagnetism (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Computer Security & Cryptography (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Artificial Intelligence (AREA)
  • Power Engineering (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Zoology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

A device useful for oral drug delivery device consisting of: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that the capsule, tablet or pill has dispersed in the gastrointestinal system. Alternatively, a switch can be used to signal ingestion of the device, and change the response of the device. In another embodiment, the instant invention is a device useful for oral drug delivery, consisting of: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non-anti-collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti-collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.

Description

ORAL DRUG COMPLIANCE MONITORING USING RADIO FREQUENCY
IDENTIFICATION TAGS
CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of United States Provisional Application
Nos. 60/683,141, filed May 20, 2005, and 60/760,903 filed January 20, 2006.
BACKGROUND OF THE INVENTION
The instant invention relates to oral drug compliance monitoring, and, more particularly, to the use of radio frequency identification tags ingested by the patient with a drug formulation.
Non-compliance of patients to drug regimens prescribed by their physicians results in increased cost of medical care, higher complication rates, as well as drug wastage. Non-compliance refers to the failure to take the prescribed dosage at the prescribed time which results in undermedication or overmedication. In a survey of 57 non-compliance studies, non-compliance ranged from 15% to as high as 95% in all study populations, regardless of medications, patient population characteristics, drug being delivered or study methodology (Greenberg, Clinical Therapeutics, 6(5):592-599, 1984).
In the clinical drug stage, accurately measuring compliance can lead to benefits such as: improved statistical reliability of a clinical study; clinical studies being completed sooner; and a determination of the effect of non-compliance as a function of the degree of non-compliance. In the therapeutic stage, accurately measuring compliance has a number of important benefits such as: warning a patient about the potential for developing a drug resistant infection related to poor compliance; and identifying a side effect of a drug related to overdosing.
Compliance to the instructions given to patients during any clinical trial is usually less than 50% in relatively short-term and less than 40% in longer-term trials using traditional methods (e.g., paper diaries) for making entries to show compliance (Vrijens and Goetghebeur, Statist. Med. 23, 531-544, 2004). A clinical trial on chronic pain patients reported only an 11% compliance with as high as 80% fake entries when paper diaries secretly instrumented to tract diary usage were given to patients (Stone et al., Control Clin. Trials. 24, 182-199, 2003) wherein on 32% of study days the paper diary was not opened, yet the compliance entries for those days exceeded 90%. A high incidence of intentional dumping of medications prior to the clinic visit by removing all or most of the medication at one time also occurs in clinical studies (Courts et al, Arch. Dis. Child. 67, 332-333, 1992; Rand et al, Am. Rev. Respir. Dis. 146, 1559-1564, 1992; Rudd et al, Clin. Pharmacol. Therap. 46, 169-176, 1989; Simmons et al, Chest. 118, 290-295, 2000). Thus, deception among noncompliant patients occurs frequently in clinical trials, and is not often revealed by the traditional monitoring methods. The result is generation of data difficult to interpret and, worse, useless to reliably predict the effectiveness of clinical trials. Better monitoring of the time of actual drug intake will help alleviate many of these issues. For example, blood levels of a drug can be corrected for the time of actual drug intake for better pharmacokinetic/ pharmacodynamic interpretations than relying on the time when patient(s) was instructed to take the medication. However, most of the present tracking devices that are utilized in clinical trials only track the initiation of the process of drug intake, i.e., by tracking the time the drug containers are opened or activated. In order to more accurately monitor the compliance of a clinical trial, a more sophisticated method of monitoring the drug intake is needed.
Confirmation of drug compliance by way of direct observation by trained persons is effective but impractical in most situations. Confirmation of drug compliance by blood or urine analysis is also impractical in most situations. Transdermal detection devices attached to the skin of a patient have been developed which detect ingested drug components through the skin and such devices can transmit a signal to a remote receiver at an external site such as a healthcare facility, see USP 6,663,846 and USPAP 2005/0031536. Electronic sensor systems have been developed which detect ingested drug components in the breath of a patient, see USPAP 2004/0081587. Radio frequency identification (RFID) tags have been incorporated into drug pills, each tag capable of identifying the type of medication, its dosage, and its lot number by way of a unique code emitted by the tag when interrogated by a corresponding radio frequency "reader", see USP 6,366,206. The RFID of the '206 patent can incorporate a biosensor that detects, for example, a change in pH to determine whether the pill has dissolved and exposed the RFID tag to the environment of the gastrointestinal system. The technology of the '206 patent requires a highly specialized spherical RFID semiconductor and biosensor. It would be an advance in the art if RFID technology could be used in a less complex manner.
SUMMARY OF THE INVENTION The instant invention is a solution, at least in part, to the above stated problems. The instant invention provides a number of new and improved alternatives for determining drug compliance using RFID tags.
More specifically, the instant invention is a device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that the capsule, tablet or pill has dispersed in the gastrointestinal system.
In another embodiment, the instant invention is a device useful for oral drug delivery, comprising: (a) a tablet, pill or capsule designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the tablet, pill or capsule, the RFID tag comprising a switch, the switch turning on or off in response to conditions in the gastrointestinal system so that if the RFID tag is interrogated before the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the capsule has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the tablet, pill or capsule has dispersed in the gastrointestinal system. In another embodiment, the instant invention is a device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non- anti-collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti- collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a gelatin capsule containing a pair of ferrite rings over an RFID tag;
Fig. 2 is an enlarged view of the oral drug delivery system of Fig. 1 after the capsule has dispersed in the gastrointestinal system;
Fig. 3 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a tablet or pill containing a cylindrical magnet over an RFID tag;
Fig. 4 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a drug tablet containing pair of ferrite disks positioned at either end of an RFID tag;
Fig. 5 is an enlarged view part in cross-section, part broken away and part in full, of an oral drug delivery system comprising a capsule containing a magnet positioned in a cavity of an RFID tag adjacent the antenna coil of the RFID tag; Fig. 6 is an enlarged view, part in cross-section and part in full, of an oral drug delivery system comprising a drug tablet containing an iron rod positioned adjacent an RFID tag;
Fig. 7 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RFID tag having an antenna shielded by a cup of gold foil; Fig. 8 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RPID tag having an antenna shielded by particles of gold embedded in the gelatin capsule;
Fig. 9 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an RFID tag having an antenna shielded by particles of gold embedded in a gum arabic coating on the RFID tag;
Fig. 10 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an RFID tag having an antenna shielded by particles of gold embedded in a gum arabic coating on the RFID tag; Fig. 11 is an enlarged view of an RFID tag having an external fine iron wire shorting the antenna of the RFID tag;
Fig. 12 is an enlarged view of the RFID tag of Fig. 11 after the RFID tag has been exposed to gastric juices for ten minutes to corrode and sever the fine iron wire;
Fig. 13 is an enlarged side view, part in cross-section and part in full, of a switch which turns on if exposed to gastric juices;
Fig. 14 is an enlarged side view, part in cross-section and part in full, of the switch of Fig. 13 after exposure to gastric juices;
Fig. 15 is an enlarged view, part in cross-section and part in full, of a gelatin capsule containing an active RFID tag powered by a kinetic generator and incorporating a conductivity switch;
Fig. 16 is a schematic drawing showing the conductivity switch of Fig. 15 in greater detail;
Fig. 17 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag powered by a battery activated by the action of the electrolyte of the gastrointestinal system in contact with the anode and cathode of the battery;
Fig. 18 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag and a dissolving link switch;
Fig. 19 is an enlarged view, part in cross-section and part in full, of a drug capsule containing an active RFID tag and a switch based sensor; Fig. 20 is an enlarged view, part in cross-section and part in full, of a drug tablet containing an active RFID tag and a capacitor based switch; Fig. 21 is an enlarged view, part in cross-section and part in full, of a drug capsule containing an active RFID tag and a temperature based switch;
Fig. 22 is a schematic view of a typical prior art RFID system including a passive RFID tag and an RFID reader or interrogator; Fig. 23 shows a cross-sectional view of a gelatin capsule containing a pair of passive non-anti-collision RFID tags being interrogated by an RFID reader;
Fig. 24 shows a cross-sectional view of a tablet containing a pair of passive non-anti- collision RFID tags being interrogated by an RFID reader; and
Fig. 25 shows a spaced apart pair of passive non-anti-collision RFID tags being interrogated by an RFID reader.
DETAILED DESCRIPTION
Referring now to Fig. 1, therein is shown an oral drug delivery system 10 of the instant invention, comprising an upper gelatin capsule portion 11 and a lower gelatin capsule portion 12. A Texas Instruments low frequency RFID tag 14 is positioned within the capsule of the system 10. The tag 14 is encapsulated in glass and includes an RFID chip encoded to identify a drug type, dose, lot number etc. The tag 14 includes an antenna. The remaining volume within the capsule of the system 10 is, of course, available to contain a drug formulation 13. A pair of ferrite rings 15 and 16 are positioned around the RFID tag 14 to alter the antenna characteristics of the RFID tag so that if the RFID tag 14 is interrogated before the capsule 11/12 disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated by the ferrite rings 15/16 to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system. The term "alter the antenna characteristics of the RFID tag" means to change the resonate frequency of the antenna and/or to reduce the effective signal strength from the antenna. The specific RFID tag used in the instant invention is not critical. For example, the RFID tag does not have to be a low frequency RFID tag. Of course, the RFID tag should be sufficiently encapsulated or otherwise protected so that it works long enough in the environment of the gastrointestinal system to fulfill its purpose. The RFID tag can be preprogrammed or programmable as is well understood in the art. Any type of RFID tag can be used in the instant invention. The RFID tag is preferably a passive RFID tag powered by the a signal from the RFID reader. However, as described below in greater detail, an active RFID tag (powered, for example, by a battery associated with the RFID tag) can also be used in the instant invention as well as a battery assisted passive RFID tag. Referring now to Fig. 2, when the oral drug delivery system of Fig. 1 is swallowed the capsule portions disperse in the stomach or intestinal tract thereby allowing the RFID tag 14 to separate from the ferrite rings 15/16 so that the response of the RFID tag 14 is sufficiently detectable to determine that the capsule has dispersed in the gastrointestinal system. It should be understood that capsules useful in the instant invention can be made of materials other than gelatin, such as hydroxypropylmethylcellulose. The capsule of the instant invention can also be made of a material, such as poly (N,N-9- diethylaminoethyl methacrylate), which disperses in an acid environment but not in water.
The specific RFID reader used is not critical in the instant invention. Preferably, the RFID reader system is battery powered and contained in a pouch worn around the waist by a belt. The RFID reader can be programmed to sense and record the type of drug(s) and times of administration thereof for later downloading or preferably for wireless downloading to, for example, healthcare professionals who could even send a reminder signal to the system to remind the patient of his/her noncompliance. Alternatively, an RFID reader system can be incorporated into a watch-like appliance worn on the wrist. Or, an RFID reader system could be clipped to a belt not unlike a cell phone clipped to a belt.
Referring now to Fig. 3, therein is shown an enlarged view, part in cross- section and part in full, of an oral drug delivery system 20 comprising a tablet or pill 21 containing a cylindrical magnet 22 over an RFID tag 23. The magnet 22 alters the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the tablet or pill 21 disperses in the gastrointestinal system, the response of the RFID tag 23 is sufficiently altered or attenuated to determine that the tablet or pill 21 has not dispersed in the gastrointestinal system and so that if the RFID tag 23 is interrogated after the tablet or pill 21 has dispersed in the gastrointestinal system, the cylindrical magnet 22 separates from the RFID tag 23 so that the response of the RFID tag 23 is sufficiently detectable to determine that the tablet or pill 21 has dispersed in the gastrointestinal system. Referring now to Fig. 4, therein is shown is an enlarged view, part in cross- section and part in full, of an oral drug delivery system 30 comprising a drug tablet 31 containing a pair of ferrite disks 32/33 positioned at either end of an RFID tag 34. The ferrite disks 32/33 alter the antenna characteristics of the RFID tag 34 so that if the RFID tag 34 is interrogated before the tablet 31 disperses in the gastrointestinal system, the response of the RFID tag 34 is sufficiently altered or attenuated to determine that the tablet 31 has not dispersed in the gastrointestinal system and so that if the RFID tag 34 is interrogated after the tablet 31 has dispersed in the gastrointestinal system, the ferrite disks 32/33 separate from the RFID tag 34 so that the response of the RFID tag 34 is sufficiently detectable to determine that the tablet 31 has dispersed in the gastrointestinal system.
Referring now to Fig. 5, therein is shown an enlarged view part in cross- section, part broken away and part in full, of an oral drug delivery system 40 comprising a capsule 41/42 containing a magnet 43 positioned in a cavity of an RFID tag 44 adjacent the antenna coil 45 of the RFID tag 44. The magnet 43 alters the antenna characteristics of the RFID tag 44 so that if the RFID tag 44 is interrogated before the system 40 disperses in the gastrointestinal system, the response of the RFID tag 44 is sufficiently altered or attenuated to determine that the system 40 has not dispersed in the gastrointestinal system and so that if the RFID tag 44 is interrogated after the system 40 has dispersed in the gastrointestinal system, the magnet 43 separates from the RFID tag 44 so that the response of the RFID tag 44 is sufficiently detectable to determine that the system 40 has dispersed in the gastrointestinal system. Alternatively, the cavity of the RFID tag can, for example and without limitation thereto, be filled with a dispersible ferrite composition that will disperse in the gastrointestinal system when the system 40 is ingested.
Referring now to Fig. 6, therein is shown an enlarged view, part in cross-section and part in full, of an oral drug delivery system 50 comprising a drug tablet 51 containing an iron rod 52 positioned adjacent an RFID tag 53. The iron rod 52 alters the antenna characteristics of the RFID tag 53 so that if the RFID tag 53 is interrogated before the system 50 disperses in the gastrointestinal system, the response of the RFID tag 53 is sufficiently altered or attenuated to determine that the system 50 has not dispersed in the gastrointestinal system and so that if the RFID tag 53 is interrogated after the system 50 has dispersed in the gastrointestinal system, the iron rod 52 separates from the RFID tag 53 so that the response of the RFID tag 53 is sufficiently detectable to determine that the system 50 has dispersed in the gastrointestinal system.
Referring now to Fig. 7, therein is shown an oral drug delivery system 10a of the instant invention, comprising an upper gelatin capsule portion 11a and a lower gelatin capsule portion 13 a. A Texas Instruments low frequency RFID tag 14a is positioned within the capsule of the system 10a. The tag 14a is encapsulated in glass 15a and includes an RFID chip 16a encoded to identify a drug type, dose, lot number etc. The tag 14a includes a copper coil antenna 18a having a ferrite core 19a in communication with the chip 16a and a capacitor 17a. The remaining volume 20a within the capsule of the system 10a is, of course, available to contain a drug formulation.
The RFID tag can be pre-programmed or programmable as is well understood in the art. The copper coil antenna 18a and ferrite core 19a are a preferred antenna system for the RFID tag 14a of the instant invention because this antenna system is compact even though the wavelength of operation is relatively long. A conventional dipole antenna of the same size as the copper coil antenna 18a requires a relatively short wavelength of operation which can complicate or even frustrate electromagnetic wave communication through human tissue since such short wavelength radiation is easily absorbed or attenuated by water.
A cup of gold foil 12a is positioned inside the upper gelatin capsule portion 11a. When the system 10a is interrogated with an RFID reader (such as the RFID reader available from, for example, Texas Instruments or from the Stoelting Company (Wood Dale, IL) it fails to respond because the gold foil 12a shields the antenna 18a. However, when the system 10a is swallowed the capsule portions 11a and 13a disperse in the stomach or intestinal tract thereby freeing the RFID tag 14a from the shielding effect of the gold foil cup 12a so that the RFID tag 14a will now respond to an RFID reader.
The upper gelatin capsule portion 1 Ia is dispersible in the stomach or intestinal tract. However, it is not critical in the embodiment shown in Fig. 7 that the upper capsule portion is so dispersible since the RFID tag will separate from the gold foil 12a as long as the lower capsule portion 13a disperses in the stomach or intestinal tract. Although it is preferable to place the gold foil 12a inside the upper capsule portion 1 Ia as shown in Fig. 1, the gold foil 12a can be placed on the outside of the upper capsule portion 11a. Although gold is the preferred material to shield the antenna 18a of the RFID tag 14a, any metal or other material can be used that is effective to shield the electromagnetic waves and which is approved for ingestion (e.g., iron and nickel are listed by the FDA as Generally Recognized As Safe for ingestion). It should be understood that capsules useful in the instant invention can be made of materials other than gelatin, such as hydroxypropylmethylcellulose. The capsule of the instant invention can also be made of a material, such as a polymer comprising N,N-9- diethylaminoethyl methacrylate, which disperses in an acid environment but not in water. Similarly, materials such as polymers comprising N,N-9-diethylaminoethyl methacrylate, hydroxypropylmethylcellulose or gelatin can be used instead of gum arabic as a coating material to contain the electromagnetic shielding material.
Referring now to Fig. 8, therein is shown another oral drug delivery system 21a of the instant invention, comprising an upper gelatin capsule portion 23 a and a lower gelatin capsule portion 22a. A Texas Instruments low frequency RFID tag 25 a is positioned within the capsule of the system 21a. The tag 25a is encapsulated in glass 26a and includes an RFID chip 27a encoded to identify a drug type, dose, lot number etc. The tag 25a includes a copper coil antenna 29a having a ferrite core 30a in communication with the chip 27a and a capacitor 28a. The remaining volume 3 Ia within the capsule of the system 21a is, of course, available to contain a drug formulation. The upper capsule 23 a comprises particles of gold 24a. When the system 21 a is interrogated with an RFID reader it fails to respond because the gold particles 24a shield the antenna 29a. However, when the system 21a is swallowed the capsule portions 23 a and 22a disperse in the stomach or intestinal tract thereby freeing the RFID tag 25a from the shielding effect of the gold particles 24a so that the RFID tag 25a will now respond to an RFID reader. The lower gelatin capsule portion 22a is dispersible in the stomach or intestinal tract. However, it is not critical in the embodiment shown in Fig. 8 that the lower capsule portion is so dispersible since the RFID tag will separate from the lower capsule portion 22a as long as the upper capsule portion 23 a disperses in the stomach or intestinal tract.
Referring now to Fig. 9, therein is shown another oral drug delivery system 32a of the instant invention, comprising an upper gelatin capsule portion 34a and a lower gelatin capsule portion 33a. A Texas Instruments low frequency RFID tag 35a is positioned within the capsule of the system 32a. The tag 35a is encapsulated in glass 36a and includes an RFID chip 37a encoded to identify a drug type, dose, lot number etc. The tag 35a includes a copper coil antenna 39a having a ferrite core 40a in communication with the chip 37a and a capacitor 38a. The remaining volume 43a within the capsule of the system 32a is, of course, available to contain a drug formulation. The upper end of the RFID tag 35a is coated with a layer of gum arabic 41a containing particles of gold 42a. When the system 32a is interrogated with an RFID reader it fails to respond because the gold particles 42a shield the antenna 39a. However, when the system 32a is swallowed the gum arabic 41a disperses in the stomach or intestinal tract thereby freeing the RFID tag 35a from the shielding effect of the gold particles 42a so that the RFID tag 35a will now respond to an RFID reader.
Referring now to Fig. 10, therein is shown another oral drug delivery system 44a of the instant invention, comprising a tablet or pill 45a containing a drug formulation. A Texas Instruments low frequency RFID tag 46a is positioned within the tablet or pill 45a. The tag 46a is encapsulated in glass 47a and includes an RFID chip 48a encoded to identify a drug type, dose, lot number etc. The tag 46a includes a copper coil antenna 50a having a ferrite core 5 Ia in communication with the chip 48a and a capacitor 49a. The RFID tag 46a is coated with a layer of gum arabic 52a containing particles of gold 53a. When the system 44a is interrogated with an RFID reader it fails to respond because the gold particles 53 a shield the antenna 50a. However, when the system 44a is swallowed the tablet or pill 45a as well as the gum arabic 52a disperses in the stomach or intestinal tract thereby freeing the RFID tag 46a from the shielding effect of the gold particles 53a so that the RFID tag 46a will now respond to an RFID reader. It should be understood that the layer of gum arabic 52a containing the gold particles 53a can also positioned on the surface of the tablet or pill 45a.
In another embodiment, the instant invention is an oral drug delivery device, comprising: (a) a drug tablet, pill or capsule designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the tablet, pill or capsule, the RFID tag comprising a switch, the switch turning on or off in response to conditions in the gastrointestinal system so that if the RFID tag is interrogated before the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the capsule has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RPBD tag signifies that the tablet, pill or capsule has dispersed in the gastrointestinal system. If the RFID tag is an active RFID tag, then the switch preferably turns on the RFID tag after the tablet, pill or capsule has dispersed in the gastrointestinal system (and thus the term "interrogate" throughout the instant invention includes reading the signal from such an active RFID tag). Alternatively, and without limitation thereto, the switch can be used to change a logic function of the RFID tag.
Referring now to Fig. 11, therein is shown an RFID tag 54a having a thin iron wire 55a projecting therefrom. The iron wire 55a serves as a "switch" for the RFID tag, turning the RFID tag off or preferably on when the iron wire 55a is severed. For example, the iron wire 55a can be positioned to short the antenna of the RFID tag 54a so that when the iron wire 55a is severed, the RFID tag 54a will respond to an RFID reader. Referring now to Fig. 12, therein is shown the RFID tag 54a of Fig. 11 after the RFID tag 54a has been exposed to the acidic conditions of the stomach. The thin iron wire 55a has been severed by corrosion. The RFID tag of Fig. 11 can thus be placed in a drug capsule or processed in a drug tablet or pill so that when the capsule, tablet or pill is ingested, the RFID tag will then respond to an RFID reader. It should be understood that other materials can be used in place of the iron wire 55a such as an electrically conductive material that disperses upon exposure in the gastrointestinal system such as a layer of a polymer comprising N,N-9- diethylaminoethyl methacrylate containing a relatively high concentration of gold particles printed on the capsule or tablet so that before its dispersion in the gastrointestinal system, the layer is electrically conductive.
Referring now to Fig. 13, therein is shown a switch system for an RFID tag (not shown) for turning the RFID tag on when the contacts of the switch are closed. The switch system of Fig. 13 includes a small case 56a having a water permeable disk 57a and a water swellable gel 62a. An upper contact 59a is connected to a first electrical lead 58a extending from the case 56a. A lower contact 60a is connected to a second electrical lead 61a extending from the bottom of the case 56a. Referring now to Fig. 14, when the switch system is exposed to water (for example after ingestion into the stomach) the water swellable gel 62a swells and pushes upper contact 59a into electrical contact with lower contact 60a, thereby closing the switch to turn off or, preferably, turn on (or off) the RFID tag. Such an RFID tag can be placed in a drug capsule or processed in a drug tablet or pill so that when the capsule, tablet or pill is ingested, the RFID tag will then respond (or stop responding) to an RFID reader. Referring now to Fig. 15, therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 10b of the instant invention including an upper gelatin capsule portion l ib and a lower gelatin capsule portion 12b. The gelatin capsule 1 lb/12b contains a drug formulation 13b and an active encapsulated RFID tag 14b powered by a kinetic generator and incorporating a conductivity detector. The kinetic generator is comprised of a magnet 18b suspended in a coil 17b. The capacitor 19b provides power to RFID circuitry 16b. When the oral drug delivery system 10b enters the gastrointestinal system, the gelatin capsule 1 lb/12b, drug formulation 13b and active RFID tag 14b are dispersed into the electrolyte solution of the gastrointestinal system and movement of the magnet 18b in the coil 17b charges capacitor 19b to power the RFID circuitry 16b. Electrodes 20ab and 20bc of a conductivity detector system activate the RFID circuitry 16b when the conductivity detector system senses the conductivity of the electrolyte solution of the gastrointestinal system. RFID circuitry 16b is connected to antenna 15b (shown as a copper coil would on a ferrite core) which transmits a signal preferably coded to identify the drug formulation, dose and lot number. Alternatively (and preferably) the kinetic generator system is replaced by a battery.
Referring now to Fig. 16, therein is shown a schematic drawing of the conductivity detector of Fig. 15 in greater detail. A p-FET transistor 22b and bias resistor 21b are incorporated to activate the RFID circuitry 16b from capacitor 19b when the conductivity of the electrolyte solution of the gastrointestinal system is detected by way of the electrodes 20ab and 20bg. Additionally, the p-FET circuit could be replaced by an n- FET5 CMOS gate, or other electronic circuits using electronic design methods well known in the art.
Referring now to Fig. 17, therein is shown is an enlarged view, part in cross- section and part in full, of a drug tablet 30b containing a drug formulation 31b and an active RFID tag 32b powered by a battery activated by the action of the electrolyte solution of the gastrointestinal system in contact with the copper anode 33b and zinc cathode 34b of the battery. In this embodiment the switch and the RFID power source are unified, i.e., when the RFID tag of tablet 30b is dispersed in the gastrointestinal system, the electrolyte solution thereof generates the electrical power for the RFID tag 32b by way of the copper anode 33b and zinc cathode 34b. The use of copper in the anode and zinc in the cathode of this embodiment are not critical in the instant invention, i.e., any suitable pair of materials can be used such as carbon and zinc or silver and zinc.
Referring now to Fig. 18, therein is shown an enlarged view, part in cross- section and part in full, of a drug tablet 40b containing drug formulation 41b and an active RFID tag 42b containing RFID circuitry 43b connected to antenna system 45b. The RFID circuitry 43b is powered by battery 44b. An electrically conducting layer of powdered silver, carbon, or other conductive material in gelatin 48b provides electrical conduction between electrodes 46b and 47b such that when the tablet 40b disperses in the gastrointestinal tract, the electrolyte solution thereof dissolves the gelatin 48b and alters the electrical conductivity between electrodes 46b and 47b thereby activating RFID circuitry 43b.
Referring now to Fig. 19, therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 50b of the instant invention including an upper gelatin capsule portion 51b and a lower gelatin capsule portion 52b. The gelatin capsule 51b/52b contains a drug formulation 53b and an active encapsulated RFID tag 54b containing RFID circuitry 55b connected to antenna system 57b. The RFID circuitry 55b is powered by battery 56b. A pad of water swellable polymer 60b is positioned so that when the oral drug delivery system 50b is dispersed in the gastrointestinal system, the electrolyte solution thereof swells the water swellable polymer 60b causing electrical conductor 58b to contact electrical conductor 59b altering the electrical conductivity between the conductors 58b and 59b thereby activating RFID circuitry 55b. It should be understood that the swelling of the water swellable polymer 60b could easily be arranged to open a switch rather than closing a switch. For example, the swelling of a water swellable polymer could easily be arranged to open a switch of the type shown in Fig. 19 or to break a thin wire. Alternatively, the space between conductors 58b and 59b could be filled with a soluble material that would dissolve in the gastrointestinal system allowing the conductors to touch and close the switch. Alternatively, a pressure switch could be used to sense the increased pressure when the active RFID tag of the instant invention was dispersed in the gastrointestinal tract.
Referring now to Fig. 20 therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery tablet 61b of the instant invention. The tablet 61b contains a drug formulation 62b and an active encapsulated RFID tag 63b containing RFID circuitry 64b connected to antenna system 66b. The RFID circuitry 64b is powered by battery 65b. A film of water swellable polymer 68b is positioned between first capacitor plate 69b and second capacitor plate 70b so that when the oral drug delivery system 61b is dispersed in the gastrointestinal tract, the electrolyte solution thereof swells the water swellable polymer 70b altering the capacitance between plates 69b and 70b thereby activating RFID circuitry 55b via electrical conductors 67b and 68b. Alternatively the capacitor plates 69b and 70b could comprise conductive wires or pads placed near the surface of 63 b such that the dielectric constant of the surroundings would change with ingestion (from air to gastrointestinal electrolyte) altering the capacitance thereby activating the RFID circuitry.
Referring now to Fig. 21, therein is shown an enlarged view, part in cross- section and part in full, of one oral drug delivery system embodiment 70b of the instant invention including an upper gelatin capsule portion 71b and a lower gelatin capsule portion 72b. The gelatin capsule 71b/72b contains a drug formulation 73b and an active encapsulated RFID tag 74b containing RFID circuitry 75b connected to antenna system 77b. The RFID circuitry 75b is powered by battery 76b. A thermistor 78b is in electrical communication with RFID circuitry 75b so that when the oral drug delivery system 70b is dispersed in the gastrointestinal tract the RFID circuitry 75b can sense the change in temperature thereby and begin sending (or altering) its signal via the antenna system 77b. The RFID circuitry 75b is preferably programmed to differentiate between the temperature profile with time that occurs when a patient swallows the oral drug delivery system 70b versus placing the oral drug delivery system 70b in, for example, a glass of hot water. Alternatively, a temperature sensitive switch can be used instead of the thermistor 78b.
In another embodiment, the instant invention is an oral drug delivery device, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non-anti- collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti- collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.
Referring now to Fig. 22, therein is shown a schematic view of a typical RFID system 10c including a passive RFID tag 1 Ic and an RFID reader or interrogator 12c which is usually associated with a host computer or microprocessor system 13c for data storage and manipulation. The RFID reader or interrogator 12c transmits a radio frequency energizing/command signal 14c which is received by the RFID tag 1 Ic to produce a return data signal 15c to be received by the reader 12c.
Referring now to Fig. 23, therein is shown shows a cross-sectional view of a gelatin capsule 21 c/22c containing a drug formulation 25c, a first non-anti-collision passive RFID tag 23c, a second non-anti-collision passive RFID tag 24c, so that if the RFID tags 23c and 24c are interrogated by energizing/command signal 28c from an RFID reader 26c before the capsule 21c/22c disperses in the gastrointestinal system, the response data signals 29c of the RFID tags 23c/24c "collide". An active RFID tag is an RFID tag having its own power source, usually a battery. A passive RFID tag is an RFID tag powered by an incoming radio frequency signal. The term "collision" is well understood in the art (see, for example, page 7 of Microchip Technology Inc., microID 13.56 MHz RFID System Design Guide (2004)) as simultaneous data signals from two or more active or passive RFID tags which interfere with each other ("collide") at the RFID reader. Thus, the term "non-anti- collision RFID tag" means an RFID tag whose data signal will collide with and interfere with the data signal from another non-anti-collision RFID tag at the RFID reader. Since the RFID tags 23c and 24c are non-anti-collision tags and since the RFID tags 23c and 24c are together in the capsule system 21c/22c, the data signals 29c from the RFID tags 23c and 24c collide at the reader 26c. A computer or microprocessor system 27c is provided for data storage and manipulation. Referring now to Fig. 24, therein is shown shows a cross-sectional view of a tablet 30c containing a drug formulation 31c, a first non-anti-collision active RFID tag 32c, a second non-anti-collision active RFID tag 33c, so that if the RFID tags 32c and 33c are interrogated by RFID reader 34c before the tablet 30c disperses in the gastrointestinal system, the data signal 37c of the RFID tags 32c/33c "collide" at the reader 34c. A computer or microprocessor system 35c is provided for data storage and manipulation.
Referring now to Fig. 25, therein is shown a spaced apart pair of passive non- anti-collision RFID tags 41c and 42c (for example if they are separated in the gastrointestinal system) being interrogated by energizing/command signal 45c/47c from an RFID reader 43c. The RFID tags 41c and 42c produce data signals 46c and 48c to be received by the reader 43 c. The RFID tag 41c is sufficiently closer to the reader 43 c than the RFID tag 42c, such that the data signals 46c and 48c can be differentiated by the reader 43 c. A computer or microprocessor system 44c is provided for data storage and manipulation. Preferably, a pair of active or passive non-anti-collision RFID tags are used in the instant invention. However, it should be understood that more than two such RFID tags can be used. Each non-anti-collision RFID tag is preferably encoded to identify (via its data signal) the drug type, dose and lot number. The specific non-anti-collision RFID tags used in the instant invention are not critical. However, it is preferred that the RFID tag be encapsulated with an inert material such as glass.
EXAMPLE 1
A series of six uniquely coded glass encapsulated animal permanent identification RFID tags (Stoelting Company, Wooddale IL) are covered with ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1). The capsules are each interrogated with a portable RFID reader (Allflex ISO Compatible RF/ID Portable Reader Model No. 930002-001) but the reader indicates "No Tag Found". The capsules are placed in a series of one liter beakers containing 900 mL of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation. The capsules disperse and the reader held at a distance of about 10 centimeters from each RFID tag responds "Tag Found" at the following times: 1.50, 1.80, 1.85, 1.87, 1.88 and 1.95 minutes.
EXAMPLE 2 A series of six uniquely coded glass encapsulated animal permanent identification
RFID tags (Stoelting Company, Wooddale IL) are covered with ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1 except that three ferrite rings are used). The capsules are each interrogated with a portable RFID reader (Allflex ISO Compatible RF/ID Portable Reader Model No. 930002-001) but the reader indicates "No Tag Found". The capsules are placed in a series of one liter beakers containing 900 niL of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation. The capsules disperse and the reader held at a distance of about 10 centimeters from each RFID tag responds "Tag Found" at the following times: 1.58, 2.22, 2.33, 3.25, 3.50 and 7.92 minutes.
EXAMPLE 3
A series of uniquely coded glass encapsulated animal permanent identification RFID tags (Stoelting Company, Wooddale IL) are covered with a pair of ferrite rings (National Magnetics Group, Bethlehem PA) and placed in gelatin capsules with a simulated drug formulation consisting of food grade lactose (substantially as shown in Fig. 1). Four healthy adult beagle dogs are dosed orally with a single capsule containing the RFID tags and ferrite rings. To read radio signals from the RFID tags, the receiver (Stoelting Company, Wooddale IL) is held manually within ~2 cm from the skin of the dog's abdominal region. The time for the first reading of the RFID tag after dissolution of the capsule and release of ferrite sleeves is determined at 1 -minute intervals until the first reading is successfully achieved. Subsequent signals are read over time (1,2,4, 8 and 24 hours) thereafter until the RFID tags and ferrite rings passed through the gastrointestinal (GI) tract to be recovered from the collected feces. The time for the RFID tags and ferrite rings to pass through the GI tract and its appearance in the feces is also monitored at each collection interval (e.g., 0-24 and 24-48 hours). The dogs in an initial experiment have free access to feed, both prior to and after dosing. The dogs in a subsequent experiment fasted overnight (-16 hours) then had free access to feed 4 hours after dosing.
In the non-fasted dogs, radio signals are read within 10.3 ±5.1 minutes after dosing with individual variation of 4 to 16 minutes. Overnight fasting prior to dosing reduces the time to the first signal detection to 6 ±1 minutes after dosing with a lower individual variation between 5 and 7 minutes. The radio signals emitted by the RFID tag are easily read by the RFID reader at subsequent time points (1,2,4,8 and 24 hours after dosing) indicating location of the device within different regions of the GI tract. All of the devices are recovered from the feces within 24-30 hours from non-fasted and between 24-48 hours from the fasted dogs. Readability of the radio signals emitted from the RFID tags is within 2-3 cm from the animal body with the exception of one tag whose signals are strong enough to be read from 10-12 cm away from the body.
EXAMPLE 4 Two Stoelting Companion Animal Permanent Identification passive RFID tags
(Allflex ISO Compliant FDX-B transponders; 12 mm implantable) together in a parallel fashion as shown in Fig. 23 are positioned in a gelatin capsule. The remainder of the capsule is filled with a drug composition. The capsule is interrogated with a portable RFID reader (Allflex ISO Compatible RF/ID Portable Reader Model No. 930002-001) but the reader indicates "No Tag Found" even at a 0 cm read distance. The capsule is placed in 900 mL of USP Simulated Gastric Fluid in a one liter beaker at 37 degrees Celsius with agitation. The capsule disperses after about two minutes and the reader held at a distance of about 10 centimeters from the one liter beaker responds "Tag Found". Six identical experiments are performed with the following times (in minutes: seconds) to successful read at a read distance of ca. 10 cm: 1:45, 2:02, 1:45, 2:10, 1:45, and 1:49.
EXAMPLE 5
A 433 MHz passive RFID tag is positioned in a gold foil modified gelatin capsule containing a drug formulation substantially as shown in Fig. 7. The capsule is interrogated with a portable RFID reader (Intermec IP3 Intellitag Portabe Reader) but the reader indicates "No Tag Found". The capsule is placed in 900 mL of USP Simulated Gastric Fluid in a one liter beaker at 37 degrees Celsius with agitation. The capsule disperses after about two minutes and the reader held at a distance of about 10 centimeters from the one liter beaker responds "Tag Found".
EXAMPLE 6
A 433 MHz active RFID tag having a conductivity switch is positioned in a large gelatin capsule containing a drug formulation substantially as shown in Fig. 15 (except the RFID tag is battery powered and the antenna is spiral wound in a dielectric). The capsule is placed in a plastic wire screen basket placed in the center of a 50 liter polyethylene tank containing 40 liters of USP Simulated Gastric Fluid at 37 degrees Celsius with agitation. A receiving dipole antenna is positioned at the bottom of the tank. Another receiving dipole antenna is positioned outside the tank. The gelatine capsule disperses in the simulated gastric fluid and the conductivity switch turns on the RFID tag which then transmits its 433 MHz signal. The signal strength received by the antenna in the tank is about 5 nanowatt. The signal strength received by the antenna outside the tank held against the tank is about 0.1 nanowatt. The signal strength received by the antenna outside the tank held 70 centimeters away from the tank is about 0.01 nanowatt. An arm held between the tank and the antenna slightly (2-3 dB) reduces the signal strength received by the antenna.
The minimum detectable signal strength received by the antenna outside the tank held even further from the tank is estimated to be about 0.0001 nanowatt. The signal strength received by the antenna outside the tank is only slightly dependent (a variation of about 1-5 dB) on the position of the antenna of the RFID tag.
CONCLUSION While the instant invention has been described above according to its preferred embodiments, it can be modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the instant invention using the general principles disclosed herein. Further, the instant application is intended to cover such departures from the present disclosure as come within the known or customary practice in the art to which this invention pertains and which fall within the limits of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill which will disperse in the gastrointestinal system; (b) an RFID tag positioned in the capsule, tablet or pill, the RFID tag comprising an antenna; (c) an object selected from the group consisting of a magnet, a ferromagnetic object, a ferrite object and an electromagnetic shielding object, the object positioned within, over or adjacent the antenna of the RFID tag to alter the antenna characteristics of the RFID tag so that if the RFID tag is interrogated before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tag is sufficiently altered or attenuated to determine that the capsule, tablet or pill has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the capsule, tablet or pill has dispersed in the gastrointestinal system, the object separates from the RFID tag so that the response of the RFID tag is sufficiently detectable to determine that the capsule, tablet or pill has dispersed in the gastrointestinal system.
2. The device of Claim 1, wherein the object of element (c) disintegrates in the gastrointestinal system.
3. The device of Claim 1 , wherein the obj ect of element (c) separates from the RFID tag in the gastrointestinal system.
4. The device of Claim 1, wherein the RFID tag is selected from the group consisting of an active RFID tag and a passive RFID tag.
5. The device of Claim 4, further comprising a drug formulation positioned in the tablet, pill or capsule.
6. A device useful for oral drug delivery, comprising: (a) a tablet, pill or capsule designed to disperse in the gastrointestinal system; (b) an RFID tag positioned in the tablet, pill or capsule, the RFID tag comprising a switch, the switch turning on or off in response to conditions in the gastrointestinal system so that if the RFID tag is interrogated before the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the capsule has not dispersed in the gastrointestinal system and so that if the RFID tag is interrogated after the tablet, pill or capsule disperses in the gastrointestinal system, the response of the RFID tag signifies that the tablet, pill or capsule has dispersed in the gastrointestinal system.
7. The device of Claim 6, wherein the RFID tag is selected from the group consisting of an active RFID tag and a passive RFID tag.
8. The device of Claim 7 further comprising a drug formulation positioned in the tablet, pill or capsule.
9. A device useful for oral drug delivery, comprising: (a) a capsule, tablet or pill designed to disperse in the gastrointestinal system; (b) a first non-anti-collision RFID tag positioned in the capsule; (c) a second non-anti-collision RFID tag positioned in the capsule, so that if the RFID tags are interrogated by an RFID reader before the capsule, tablet or pill disperses in the gastrointestinal system, the response of the RFID tags collide and so that after the dispersible material of the capsule has dispersed in the gastrointestinal system thereby allowing the first and second non-anti-collision tags to separate from each other, then the response of the RFID tags is sufficiently different from each other to determine that the capsule has dispersed in the gastrointestinal system.
10. The device of Claim 9, wherein the RFID tag is selected from the group consisting of an active RFID tag and a passive RFID tag.
11. The device of Claim 10, further comprising a drug formulation positioned in the tablet, pill or capsule.
PCT/US2006/019079 2005-05-20 2006-05-18 Oral drug compliance monitoring using radio frequency identification tags WO2006127355A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002609007A CA2609007A1 (en) 2005-05-20 2006-05-18 Oral drug compliance monitoring using radio frequency identification tags
JP2008512470A JP4933538B2 (en) 2005-05-20 2006-05-18 Oral medication monitoring using radio frequency identification signs
EP06770493A EP1885343B1 (en) 2005-05-20 2006-05-18 Oral drug compliance monitoring using radio frequency identification tags
CN2006800251198A CN101217945B (en) 2005-05-20 2006-05-18 Oral drug compliance monitoring using radio frequency identification tags
DK06770493.2T DK1885343T3 (en) 2005-05-20 2006-05-18 Monitoring an Oral Drug Compliance Using Radio Frequency Identification Tags (RFID Tags)
AT06770493T ATE526952T1 (en) 2005-05-20 2006-05-18 MONITORING CORRECT DELIVERY OF ORAL DRUGS USING RADIO FREQUENCY IDENTIFICATION LABELS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68314105P 2005-05-20 2005-05-20
US60/683,141 2005-05-20
US76090306P 2006-01-20 2006-01-20
US60/760,903 2006-01-20

Publications (2)

Publication Number Publication Date
WO2006127355A2 true WO2006127355A2 (en) 2006-11-30
WO2006127355A3 WO2006127355A3 (en) 2007-03-29

Family

ID=36950563

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019079 WO2006127355A2 (en) 2005-05-20 2006-05-18 Oral drug compliance monitoring using radio frequency identification tags

Country Status (9)

Country Link
US (1) US7382263B2 (en)
EP (1) EP1885343B1 (en)
JP (1) JP4933538B2 (en)
CN (1) CN101217945B (en)
AT (1) ATE526952T1 (en)
CA (1) CA2609007A1 (en)
DK (1) DK1885343T3 (en)
TW (1) TW200706180A (en)
WO (1) WO2006127355A2 (en)

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008089232A1 (en) * 2007-01-16 2008-07-24 Dow Global Technologies Inc. Oral drug capsule component incorporating a communication device
WO2011033310A1 (en) * 2009-09-17 2011-03-24 William John Martin Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders
EP2310989A2 (en) * 2008-07-07 2011-04-20 Mario W. Cardullo Dynamically distributable nano rfid device and related method
WO2011127252A2 (en) * 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
US8674825B2 (en) 2005-04-28 2014-03-18 Proteus Digital Health, Inc. Pharma-informatics system
JP2014054558A (en) * 2007-02-01 2014-03-27 Proteus Digital Health Inc Ingestible event marker system
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
WO2015083105A1 (en) * 2013-12-03 2015-06-11 Capsugel Belgium Nv Dosage form articles
EP3010084A1 (en) * 2014-10-17 2016-04-20 Synoste OY A device with a receiving antenna and a related power transfer system
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
WO2016091964A1 (en) * 2014-12-10 2016-06-16 Schreiner Group Gmbh & Co. Kg Arrangement for a humidity sensor and method for producing the arrangement for a humidity sensor
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
GB2547481A (en) * 2016-02-22 2017-08-23 Bgt Mat Ltd Identifiable ticket and monitoring system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
EP3367386A1 (en) 2006-05-02 2018-08-29 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US10076099B2 (en) 2014-11-19 2018-09-18 InnovaSea Marine Systems Canada Inc. Predation detection animal tracking tag
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11612321B2 (en) 2007-11-27 2023-03-28 Otsuka Pharmaceutical Co., Ltd. Transbody communication systems employing communication channels
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092224B2 (en) * 1995-11-22 2012-01-10 James A. Jorasch Systems and methods for improved health care compliance
US8055509B1 (en) * 2000-03-10 2011-11-08 Walker Digital, Llc Methods and apparatus for increasing and/or for monitoring a party's compliance with a schedule for taking medicines
US8479988B2 (en) * 2000-11-16 2013-07-09 Gsl Solutions, Inc. System for pharmacy tracking and customer id verification
US7747477B1 (en) * 2000-11-16 2010-06-29 Gsl Solutions, Inc. Pharmacy supply tracking and storage system
US7887146B1 (en) 2001-08-18 2011-02-15 Gsl Solutions, Inc. Suspended storage system for pharmacy
US8224664B1 (en) 2000-11-16 2012-07-17 Gsl Solutions, Inc. Portable prescription order distribution cart and tracking system
US20090230189A1 (en) * 2000-11-16 2009-09-17 Shelton Louie Scanning Wand For Pharmacy Tracking and Verification
US7672859B1 (en) * 2000-11-16 2010-03-02 Gsl Solutions, Inc. Prescription order position tracking system and method
FR2841021B1 (en) * 2002-06-13 2004-12-24 Systemig Sa MONITORING AND / OR MONITORING DEVICE USING AN ELECTRONIC LABEL, A READER AND A STATUS ENCODER
US7414534B1 (en) * 2004-11-09 2008-08-19 Pacesetter, Inc. Method and apparatus for monitoring ingestion of medications using an implantable medical device
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US20090215146A1 (en) * 2005-05-24 2009-08-27 Responsif Gmbh Method for Producing Virus-Type Particles Containing an Active Substance
EP1903936B1 (en) * 2005-07-20 2018-08-29 Neil R. Euliano Electronic pill for monitoring medication compliance
US9047746B1 (en) 2005-07-20 2015-06-02 Neil Euliano Electronic medication compliance monitoring system and associated methods
US8547248B2 (en) 2005-09-01 2013-10-01 Proteus Digital Health, Inc. Implantable zero-wire communications system
CA2649447A1 (en) * 2006-04-25 2007-11-08 Dow Global Technologies Inc. Oral drug compliance monitoring using magnetic-field sensors
WO2008008281A2 (en) 2006-07-07 2008-01-17 Proteus Biomedical, Inc. Smart parenteral administration system
US20080020037A1 (en) * 2006-07-11 2008-01-24 Robertson Timothy L Acoustic Pharma-Informatics System
US8054140B2 (en) 2006-10-17 2011-11-08 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
CN101534711B (en) * 2006-10-31 2012-11-14 皇家飞利浦电子股份有限公司 Design of swallowable multi-nozzle, dosing device for releasing medicines in the gastrointesinal tract
EP2069004A4 (en) 2006-11-20 2014-07-09 Proteus Digital Health Inc Active signal processing personal health signal receivers
US7710269B2 (en) * 2007-01-11 2010-05-04 University Of Southern California Systems and methods to prevent counterfeit, grey and black market proliferation of pharmaceutical, medical and other products
WO2008093578A1 (en) * 2007-01-30 2008-08-07 Olympus Medical Systems Corp. Device for checking for lumen passage, method of melting the same and method of producing the same
AU2012244231B2 (en) * 2007-02-14 2014-09-18 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
WO2008112578A1 (en) 2007-03-09 2008-09-18 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US7777631B2 (en) * 2007-04-29 2010-08-17 James Neil Rodgers Body chip
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
US20090009332A1 (en) * 2007-07-03 2009-01-08 Endotronix, Inc. System and method for monitoring ingested medication via rf wireless telemetry
US7755488B2 (en) 2007-09-21 2010-07-13 Baxter International Inc. Access disconnection detection system
US8707964B2 (en) 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
EP2211974A4 (en) 2007-10-25 2013-02-27 Proteus Digital Health Inc Fluid transfer port information system
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8333754B2 (en) 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8419638B2 (en) 2007-11-19 2013-04-16 Proteus Digital Health, Inc. Body-associated fluid transport structure evaluation devices
US20090149839A1 (en) * 2007-12-11 2009-06-11 Hyde Roderick A Treatment techniques using ingestible device
JP2011513865A (en) 2008-03-05 2011-04-28 プロテウス バイオメディカル インコーポレイテッド Multi-mode communication ingestible event marker and system and method of using the same
US20090247850A1 (en) * 2008-03-28 2009-10-01 Nellcor Puritan Bennett Llc Manually Powered Oximeter
US20110163871A1 (en) * 2008-04-01 2011-07-07 Shmuel Einav Rfid monitoring of drug regimen compliance
AU2009281876B2 (en) 2008-08-13 2014-05-22 Proteus Digital Health, Inc. Ingestible circuitry
US8036748B2 (en) * 2008-11-13 2011-10-11 Proteus Biomedical, Inc. Ingestible therapy activator system and method
US7948385B2 (en) * 2008-12-09 2011-05-24 General Electric Company Systems and methods for using ferrite alignment keys in wireless remote sensors
JP2012511961A (en) 2008-12-11 2012-05-31 プロテウス バイオメディカル インコーポレイテッド Judgment of digestive tract function using portable visceral electrical recording system and method using the same
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
TWI503101B (en) 2008-12-15 2015-10-11 Proteus Digital Health Inc Body-associated receiver and method
TWI602561B (en) * 2009-01-06 2017-10-21 波提亞斯數位康健公司 Pharmaceutical dosages delivery system
WO2010080765A2 (en) * 2009-01-06 2010-07-15 Proteus Biomedical, Inc. High-throughput production of ingestible event markers
US8540664B2 (en) 2009-03-25 2013-09-24 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
EP2432458A4 (en) * 2009-05-12 2014-02-12 Proteus Digital Health Inc Ingestible event markers comprising an ingestible component
KR20120081583A (en) * 2009-08-17 2012-07-19 더 리전트 오브 더 유니버시티 오브 캘리포니아 Distributed external and internal wireless sensor systems for characterization of surface and subsurface biomedical structure and condition
EP2467707A4 (en) 2009-08-21 2014-12-17 Proteus Digital Health Inc Apparatus and method for measuring biochemical parameters
US9554739B2 (en) 2009-09-29 2017-01-31 Covidien Lp Smart cable for coupling a medical sensor to an electronic patient monitor
EP2314154A1 (en) * 2009-10-26 2011-04-27 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Bolus System
UA109424C2 (en) * 2009-12-02 2015-08-25 PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS
JP5330609B2 (en) 2010-02-01 2013-10-30 プロテウス デジタル ヘルス， インコーポレイテッド Data collection system on two wrists
US9078610B2 (en) * 2010-02-22 2015-07-14 Covidien Lp Motion energy harvesting with wireless sensors
US9112263B2 (en) 2010-02-25 2015-08-18 Stmicroelectronics S.R.L. Electronic communications device with antenna and electromagnetic shield
US20120165794A1 (en) * 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US11244747B2 (en) 2014-10-16 2022-02-08 Gsl Solutions, Inc. Pharmacy security system
US12046342B2 (en) 2011-02-14 2024-07-23 Gsl Solutions, Inc. Pharmacy stock supply tracking system
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
JP2014514039A (en) * 2011-03-17 2014-06-19 ギブン イメージング リミテッド Capsule phototherapy
US9687638B2 (en) * 2011-03-24 2017-06-27 Medimetrics Personalized Drug Delivery Swallowable medication capsule
US10445846B2 (en) 2011-04-14 2019-10-15 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US9626650B2 (en) 2011-04-14 2017-04-18 Elwha Llc Cost-effective resource apportionment technologies suitable for facilitating therapies
US20130046153A1 (en) 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Systematic distillation of status data relating to regimen compliance
US20130099928A1 (en) * 2011-10-19 2013-04-25 Glenn Daly Method and System for Detecting Duress Using Proximity Card
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
TWI477410B (en) * 2012-02-03 2015-03-21 Univ Nat Taipei Technology Object wear detection device
KR20150038038A (en) 2012-07-23 2015-04-08 프로테우스 디지털 헬스, 인코포레이티드 Techniques for manufacturing ingestible event markers comprising an ingestible component
US9131842B2 (en) 2012-08-16 2015-09-15 Rock West Solutions, Inc. System and methods for locating relative positions of multiple patient antennas
US10045713B2 (en) 2012-08-16 2018-08-14 Rock West Medical Devices, Llc System and methods for triggering a radiofrequency transceiver in the human body
KR101565013B1 (en) 2012-10-18 2015-11-02 프로테우스 디지털 헬스, 인코포레이티드 Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
KR101510512B1 (en) * 2013-02-07 2015-04-10 민원기 System for monitoring drug complicance of oral feeding medicine using personal radio frequency identification tag and method thereof
US9211498B2 (en) 2013-03-15 2015-12-15 Makefield Llc Functional desiccants
US8981939B2 (en) 2013-05-28 2015-03-17 International Business Machines Corporation System and method for verifying patient compliance
WO2015044722A1 (en) 2013-09-24 2015-04-02 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
JP6767261B2 (en) 2013-10-22 2020-10-14 ロック ウエスト メディカル デバイス， エルエルシー A system for locating a swallowable tablet sensor with three transmitting elements
EP2777802B1 (en) * 2013-12-03 2016-03-16 Capsugel Belgium NV Multi-compartment dosage form articles
US10521561B1 (en) 2013-12-17 2019-12-31 Etectrx, Inc. Electronic compliance system and associated methods
DE18211682T1 (en) * 2014-03-07 2019-11-28 InnovaSea Marine Systems Canada Inc. FISH TRACKING LABEL WITH PREDATION DETECTION
EP2963591B1 (en) * 2014-06-30 2019-09-18 Neopost Technologies Attachment assembly having identification capability
US9731853B2 (en) 2014-08-05 2017-08-15 Makefield Llc Networked notification for dispensable units
EP3021245A1 (en) 2014-10-06 2016-05-18 Carebay Europe Ltd. Information provider system
FR3036028B1 (en) * 2015-05-15 2017-06-23 Univ Paris Descartes RFID DEVICE ADAPTED TO BE INGED, DETECTION KIT AND ASSOCIATED SYSTEM
JP6742605B2 (en) * 2015-12-28 2020-08-19 国立大学法人東北大学 Battery and electronic equipment
US10588823B1 (en) * 2017-07-12 2020-03-17 Rakesh Arora System for the tracking, dispensing, and administering of a medicament in a programmable encapsulation
US11786142B2 (en) * 2019-01-11 2023-10-17 Tokitae Llc Ingestible RFID tag and reader system
US11094407B2 (en) 2019-06-13 2021-08-17 International Business Machines Corporation Electronics miniaturization platform for medication verification and tracking

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844076A (en) * 1988-08-26 1989-07-04 The Johns Hopkins University Ingestible size continuously transmitting temperature monitoring pill
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US6366206B1 (en) * 1999-06-02 2002-04-02 Ball Semiconductor, Inc. Method and apparatus for attaching tags to medical and non-medical devices

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5170801A (en) * 1990-10-02 1992-12-15 Glaxo Inc. Medical capsule device actuated by radio-frequency (rf) signal
US5941251A (en) 1994-10-11 1999-08-24 Ep Technologies, Inc. Systems for locating and guiding operative elements within interior body regions
US5778882A (en) * 1995-02-24 1998-07-14 Brigham And Women's Hospital Health monitoring system
WO2000037114A2 (en) * 1998-12-21 2000-06-29 Sequella, Inc. Methods and compositions comprising monitoring devices
US6297734B1 (en) 1999-09-23 2001-10-02 Northrop Grumman Corporation Randomization of transmit time
US6294997B1 (en) * 1999-10-04 2001-09-25 Intermec Ip Corp. RFID tag having timing and environment modules
CA2390261C (en) * 1999-11-08 2014-04-22 University Of Florida Research Foundation, Inc. Marker detection method and apparatus to monitor drug compliance
GB9930000D0 (en) * 1999-12-21 2000-02-09 Phaeton Research Ltd An ingestible device
US6632175B1 (en) * 2000-11-08 2003-10-14 Hewlett-Packard Development Company, L.P. Swallowable data recorder capsule medical device
US6753783B2 (en) * 2001-03-30 2004-06-22 Augmentech, Inc. Patient positioning monitoring apparatus and method of use thereof
US20030117787A1 (en) * 2001-10-17 2003-06-26 Laird Technologies, Inc. Method and apparatus for EMI shielding
US7414416B2 (en) 2002-03-06 2008-08-19 Polymer Aging Concepts Inc. Electrical condition monitoring method for polymers
CA2387106A1 (en) 2002-05-21 2003-11-21 Information Mediary Corporation Method for measuring temperature using a remote, passive, calibrated rf/rfid tag including a method for calibration
US6927687B2 (en) * 2002-07-09 2005-08-09 Battelle Memorial Institute K1-53 Method and apparatus for determining average environmental conditions
US7015802B2 (en) 2002-08-08 2006-03-21 Forster Ian J Vehicle tag reader
US7573370B2 (en) 2002-09-05 2009-08-11 Honeywell International Inc. Method and device for storing and distributing information in an RFID tag
US6776165B2 (en) * 2002-09-12 2004-08-17 The Regents Of The University Of California Magnetic navigation system for diagnosis, biopsy and drug delivery vehicles
US6791603B2 (en) 2002-12-03 2004-09-14 Sensormatic Electronics Corporation Event driven video tracking system
US6950028B2 (en) * 2003-04-25 2005-09-27 Stephen Eliot Zweig Electronic time-temperature indicator
US6970070B2 (en) * 2003-05-08 2005-11-29 Rsa Security Inc. Method and apparatus for selective blocking of radio frequency identification devices
JP2005033461A (en) * 2003-07-11 2005-02-03 Mitsubishi Materials Corp Rfid system and structure of antenna therein
JP2005086244A (en) * 2003-09-04 2005-03-31 Dainippon Printing Co Ltd Rf id coating tool
US8295920B2 (en) 2003-10-24 2012-10-23 Medrad, Inc. System for detecting fluid changes and sensoring devices therefor
US20050174236A1 (en) * 2004-01-29 2005-08-11 Brookner George M. RFID device tracking and information gathering
EP1776688B1 (en) 2004-03-19 2013-05-08 Arbitron Inc. Gathering data concerning publication usage
US7145453B2 (en) * 2004-09-02 2006-12-05 The Dow Chemical Company Harmonic wireless transponder sensor and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US4844076A (en) * 1988-08-26 1989-07-04 The Johns Hopkins University Ingestible size continuously transmitting temperature monitoring pill
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US6366206B1 (en) * 1999-06-02 2002-04-02 Ball Semiconductor, Inc. Method and apparatus for attaching tags to medical and non-medical devices

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAMBERT A ET AL: "AUTONOMOUS TELEMETRIC CAPSULE TO EXPLORE THE SMALL BOWEL" MEDICAL AND BIOLOGICAL ENGINEERING AND COMPUTING, SPRINGER, HEILDELBERG, DE, vol. 29, no. 2, 1 March 1991 (1991-03-01), pages 191-196, XP000230962 ISSN: 0140-0118 *

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9623056B2 (en) 2000-07-20 2017-04-18 Crestovo Llc Probiotic recolonisation therapy
US9867858B2 (en) 2000-07-25 2018-01-16 Crestovo Holdings Llc Probiotic recolonisation therapy
US9572842B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US9901604B2 (en) 2000-07-25 2018-02-27 Crestovo Holdings Llc Probiotic recolonisation therapy
US9789140B2 (en) 2000-07-25 2017-10-17 Crestovo Holdings Llc Probiotic recolonisation therapy
US9610308B2 (en) 2000-07-25 2017-04-04 Crestovo Llc Probiotic recolonisation therapy
US9682108B2 (en) 2000-07-25 2017-06-20 Crestovo Llc Probiotic recolonisation therapy
US9572841B2 (en) 2000-07-25 2017-02-21 Crestovo Llc Probiotic recolonisation therapy
US10369175B2 (en) 2000-07-25 2019-08-06 Crestovo Holdings Llc Probiotic recolonisation therapy
US9468658B2 (en) 2000-07-25 2016-10-18 Crestovo Llc Probiotic recolonisation therapy
US9962414B2 (en) 2000-07-25 2018-05-08 Crestovo Holdings Llc Probiotic recolonisation therapy
US9737574B2 (en) 2000-07-25 2017-08-22 Crestovo Llc Probiotic recolonisation therapy
US9408872B2 (en) 2000-07-25 2016-08-09 Crestovo Llc Probiotic recolonisation therapy
US10772919B2 (en) 2000-07-25 2020-09-15 Crestovo Holdings Llc Probiotic recolonisation therapy
US9320763B2 (en) 2000-07-25 2016-04-26 Thomas Julius Borody Probiotic recolonisation therapy
US8674825B2 (en) 2005-04-28 2014-03-18 Proteus Digital Health, Inc. Pharma-informatics system
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US10610128B2 (en) 2005-04-28 2020-04-07 Proteus Digital Health, Inc. Pharma-informatics system
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US10542909B2 (en) 2005-04-28 2020-01-28 Proteus Digital Health, Inc. Communication system with partial power source
US11476952B2 (en) 2005-04-28 2022-10-18 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US10517507B2 (en) 2005-04-28 2019-12-31 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
EP3367386A1 (en) 2006-05-02 2018-08-29 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US11928614B2 (en) 2006-05-02 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens
US11357730B2 (en) 2006-10-25 2022-06-14 Otsuka Pharmaceutical Co., Ltd. Controlled activation ingestible identifier
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
WO2008089232A1 (en) * 2007-01-16 2008-07-24 Dow Global Technologies Inc. Oral drug capsule component incorporating a communication device
JP2010516303A (en) * 2007-01-16 2010-05-20 ダウ グローバル テクノロジーズ インコーポレイティド Oral drug capsule components incorporating communication devices
JP2015107342A (en) * 2007-02-01 2015-06-11 プロテウス デジタル ヘルス， インコーポレイテッド Ingestible event marker systems
US10441194B2 (en) 2007-02-01 2019-10-15 Proteus Digital Heal Th, Inc. Ingestible event marker systems
JP2014054558A (en) * 2007-02-01 2014-03-27 Proteus Digital Health Inc Ingestible event marker system
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US11612321B2 (en) 2007-11-27 2023-03-28 Otsuka Pharmaceutical Co., Ltd. Transbody communication systems employing communication channels
EP2310989A2 (en) * 2008-07-07 2011-04-20 Mario W. Cardullo Dynamically distributable nano rfid device and related method
EP2310989A4 (en) * 2008-07-07 2013-03-13 Mario W Cardullo Dynamically distributable nano rfid device and related method
US10682071B2 (en) 2008-07-08 2020-06-16 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US11217342B2 (en) 2008-07-08 2022-01-04 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker data framework
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
WO2011033310A1 (en) * 2009-09-17 2011-03-24 William John Martin Encapsulated intestinal flora extracted from feces for use in the treatment of gastrointestinal disorders
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US10305544B2 (en) 2009-11-04 2019-05-28 Proteus Digital Health, Inc. System for supply chain management
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
AU2011237612B2 (en) * 2010-04-07 2016-05-12 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
WO2011127252A3 (en) * 2010-04-07 2012-02-23 Proteus Biomedical, Inc. Miniature ingestible device
WO2011127252A2 (en) * 2010-04-07 2011-10-13 Proteus Biomedical, Inc. Miniature ingestible device
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US11173290B2 (en) 2010-04-07 2021-11-16 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US11173183B2 (en) 2010-08-04 2021-11-16 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11207356B2 (en) 2010-08-04 2021-12-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890308B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11890307B2 (en) 2010-08-04 2024-02-06 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11850269B2 (en) 2010-08-04 2023-12-26 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10278997B2 (en) 2010-08-04 2019-05-07 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11541080B2 (en) 2010-08-04 2023-01-03 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504403B2 (en) 2010-08-04 2022-11-22 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10617724B2 (en) 2010-08-04 2020-04-14 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10328107B2 (en) 2010-08-04 2019-06-25 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11491193B2 (en) 2010-08-04 2022-11-08 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10610551B2 (en) 2010-08-04 2020-04-07 Crestovo Holdings, Inc. Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11129859B2 (en) 2010-08-04 2021-09-28 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11103541B2 (en) 2010-08-04 2021-08-31 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11065284B2 (en) 2010-08-04 2021-07-20 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10463702B2 (en) 2010-08-04 2019-11-05 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10987385B2 (en) 2010-08-04 2021-04-27 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10857188B2 (en) 2010-08-04 2020-12-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10849937B2 (en) 2010-08-04 2020-12-01 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10064899B1 (en) 2010-08-04 2018-09-04 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9962413B2 (en) 2010-08-04 2018-05-08 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10022406B2 (en) 2010-08-04 2018-07-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US10675309B2 (en) 2010-08-04 2020-06-09 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US10028980B2 (en) 2011-03-09 2018-07-24 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10251914B2 (en) 2011-03-09 2019-04-09 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US11801269B2 (en) 2011-03-09 2023-10-31 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286012B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US10286011B2 (en) 2011-03-09 2019-05-14 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
US9649343B2 (en) 2011-03-09 2017-05-16 National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) Compositions and methods for transplantation of colon microbiota
US11229378B2 (en) 2011-07-11 2022-01-25 Otsuka Pharmaceutical Co., Ltd. Communication system with enhanced partial power source and method of manufacturing same
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US12084727B2 (en) 2012-05-25 2024-09-10 Arizona Board Of Regents On Behalf Of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11542560B2 (en) 2012-05-25 2023-01-03 Board of Regents on Behalf of Arizona State University Microbiome markers and therapies for autism spectrum disorders
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11741771B2 (en) 2013-03-15 2023-08-29 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US10421658B2 (en) 2013-08-30 2019-09-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US11102038B2 (en) 2013-09-20 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10498572B2 (en) 2013-09-20 2019-12-03 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10097388B2 (en) 2013-09-20 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US9980905B2 (en) 2013-12-03 2018-05-29 Capsugel Belgium Nv Dosage form articles
WO2015083105A1 (en) * 2013-12-03 2015-06-11 Capsugel Belgium Nv Dosage form articles
US11950615B2 (en) 2014-01-21 2024-04-09 Otsuka Pharmaceutical Co., Ltd. Masticable ingestible product and communication system therefor
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10511193B2 (en) 2014-10-17 2019-12-17 Synoste Oy Device with a receiving antenna and a related power transfer system
EP3010084A1 (en) * 2014-10-17 2016-04-20 Synoste OY A device with a receiving antenna and a related power transfer system
US10076099B2 (en) 2014-11-19 2018-09-18 InnovaSea Marine Systems Canada Inc. Predation detection animal tracking tag
WO2016091964A1 (en) * 2014-12-10 2016-06-16 Schreiner Group Gmbh & Co. Kg Arrangement for a humidity sensor and method for producing the arrangement for a humidity sensor
US10821138B2 (en) 2015-05-14 2020-11-03 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11123377B2 (en) 2015-05-14 2021-09-21 Finch Therapeutics Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
US11202808B2 (en) 2015-05-22 2021-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
GB2547481A (en) * 2016-02-22 2017-08-23 Bgt Mat Ltd Identifiable ticket and monitoring system therefor
US11357801B2 (en) 2016-06-15 2022-06-14 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US11819523B2 (en) 2016-07-01 2023-11-21 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10797758B2 (en) 2016-07-22 2020-10-06 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10195235B2 (en) 2016-08-03 2019-02-05 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10561690B2 (en) 2016-08-03 2020-02-18 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11071759B2 (en) 2016-08-03 2021-07-27 Finch Therapeutics Holdings Llc Methods for treating ulcerative colitis
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11793419B2 (en) 2016-10-26 2023-10-24 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11433102B2 (en) 2017-04-05 2022-09-06 Finch Therapeutics Holdings Llc Compositions and methods for treating Parkinson's disease (PD) and related disorders
US11529375B2 (en) 2017-04-05 2022-12-20 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders

Also Published As

Publication number Publication date
WO2006127355A3 (en) 2007-03-29
CA2609007A1 (en) 2006-11-30
US20060289640A1 (en) 2006-12-28
TW200706180A (en) 2007-02-16
US7382263B2 (en) 2008-06-03
ATE526952T1 (en) 2011-10-15
JP2008540047A (en) 2008-11-20
EP1885343B1 (en) 2011-10-05
EP1885343A2 (en) 2008-02-13
CN101217945A (en) 2008-07-09
CN101217945B (en) 2012-07-11
JP4933538B2 (en) 2012-05-16
DK1885343T3 (en) 2012-01-16

Similar Documents

Publication Publication Date Title
EP1885343B1 (en) Oral drug compliance monitoring using radio frequency identification tags
JP5461999B2 (en) Oral drug capsule components incorporating communication devices
US10765360B2 (en) Electronic medication compliance monitoring system and associated methods
US10292642B2 (en) Electronic medication compliance monitoring system and associated methods
US9183724B2 (en) System to monitor the ingestion of medicines
US7782189B2 (en) System to monitor the ingestion of medicines
US20100322859A1 (en) Oral drug compliance monitoring using magnetic-field sensors
US20140309505A1 (en) Electronic medication compliance monitoring system and associated methods
CA2909033C (en) Electronic medication compliance monitoring system and associated methods
AU2015243053A1 (en) Electronic medication compliance monitoring system and associated methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680025119.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2609007

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006770493

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008512470

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 5249/CHENP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU